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ABSTRACT 
The effects of Mycoplasma bovis on bovine lympho-proliferation and viability were 
studied. Incubation of bovine peripheral blood mononuclear cells (PBMC) in vitro with M. 
bovis induced lymphocyte apoptosis as monitored by Annexin V binding, propidium iodide 
incorporation, and DNA fragmentation. The induction of lymphocyte death was abrogated 
by chloramphenicol, indicating that lymphocyte death was dependent upon prokaryotic 
protein production. 
In attempts to better define the lymphotoxic factors associated with M. bovis, the task 
of isolating the M. bovis lymphocyte inhibitory or cytotoxic factor was undertaken. Using 
size exclusion chromatography a fraction able to suppress bovine lympho-proliferative 
responses to ConA was isolated. MALDI-TOF analysis of the suppressive fraction revealed 
one dominant peak (M.W. of 2,970 daltons) unique to the suppressive fraction. N-terminal 
sequencing of the suppressive fraction revealed a 19 amino acid sequence homologous to the 
C-terminus of the M. bovis theoretical gene encoding Vsp-L (variable surface protein-L) as 
determined by a BLAST search against the NCBI national protein database. The sequence 
data was used to construct primers for PCR amplification of the vspL gene domain 
corresponding to the last 26 amino acids of the VspL's protein C-terminus. This PCR 
product was cloned and inserted into an expression plasmid as a GST-fusion protein 
engineered with a thrombin recognition cleavage site between GST and the recombinant 
peptide (to facilitate purification of the peptide). Upon purification, the peptide Mb-LIP (M. 
bovis lymphocyte inhibitory peptide) was tested for lympho-proliferative inhibition. The 
recombinant peptide inhibited bovine lymphocyte proliferation responses to ConA and CD3 
stimulation in vitro. Further study indicated that incubation of PBMCs with the recombinant 
peptide decreased the number of viable lymphocytes in culture. The recombinant peptide 
Mb-LIP is therefore considered a lymphotoxic peptide. This marks the first described 
characterization of a mycoplasmal product able to inhibit naive lymphocyte function. 
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CHAPTER 1. GENERAL INTRODUCTION 
Mycoplasma bovis is a wall-less prokaryotic (class Mollicutes) pathogen of cattle 
causing multiple diseases, including mastitis, pneumonia, and arthritis. As with other 
mycoplasma infectious agents M. bovis infections are known to be chronic in nature, being 
isolated from animals for months or even years after the initial infection. While the 
mechanism used by M. bovis to maintain a presence within its bovine host is unknown, two 
general mechanisms have been proposed, antigenic variation and immune response 
modulation. 
Antigenic variation is accomplished through the variable expression of surface 
proteins or altering the primary structure of surface antigens. The M. bovis genome codes for 
a family of surface proteins known as Vsps (variable surface proteins) that are variable in 
expression, size, and antigenicity. The plasticity within the expression of these highly 
antigenic surface proteins is believed to be one mechanism of immune evasion. While these 
proteins appear to have a passive role in M. bovis pathogenicity, some of them play an active 
role in cellular adhesion. Despite years of research, products of some vsp genes have not 
been identified. In addition, roles of individual Vsp proteins in M. bovis pathogenicity are as 
of yet unknown. 
Immune response modulation is accomplished by down-regulation or nonspecific 
activation of host immune cells. Through these modulations Mycoplasma species can elude 
immune detection. Prior to the discovery of Vsps, M. bovis was shown to inhibit lymphocyte 
proliferation in response to lectin mitogens. This lympho-suppression could be used to help 
explain the chronicity of M. bovis infections. Presumably by limiting adaptive responses, M. 
bovis can persist within its host. The research described herein was undertaken with the 
intention of better understanding M. bovis and bovine lymphocyte interactions by isolating 
the M. bovis produced factor(s) able to inhibit lympho-proliferation. 
The lympho-suppressive factor(s) produced by M. bovis was determined to be heat 
labile and non-toxic as lymphocyte viability was not affected by incubation with M. bovis. 
However, with the use of modern techniques, M. bovis was shown to decrease lymphocyte 
viability in vitro thru the induction of apoptosis. In addition to the observation of M. bovis's 
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ability to induce bovine lymphocyte apoptosis, the isolation and characterization of a 
lympho-inhibitory peptide produced by M. bovis was also accomplished. The peptide, 
referred to as M. bovis lymphocyte inhibitory peptide (Mb-LIP), is homologous to the C-
terminus of VspL. This discovery, therefore, defines a pathogenic role for an individual Vsp 
gene product. 
Dissertation Organization 
This dissertation is comprised of a literature review, two manuscripts, a brief 
summary of the work, and two appendices. The literature review is divided into three 
sections; 1) a general background of mycoplasmas in relation to disease and immunity, 2) a 
introduction to Mycoplasma bovis emphasizing immunopathology, and 3) a section serving 
as an overview of T-lymphocyte activation and suppression (including mycoplasma-
mediated immune suppression). The central portion of this thesis contains two manuscripts. 
The first (chapter 3), Mycoplasma bovis induces apoptosis of bovine lymphocytes, has been 
published in FEMS Immunology and Medical Microbiology'. The second manuscript 
(chapter 4), Isolation and characterization of a lymphosuppressive peptide produced by 
Mycoplasma bovis, will be submitted to Biochemical and Biophysical Research 
Communications for publication. A brief summary section discussing the implications of the 
work and possible directions for continued studies follows these chapters. The central text of 
the dissertation is immediately followed by acknowledgements. 
The dissertation is concluded with two appendices highlighting cellular and humoral 
immune responses to M. bovis antigens. Appendix A, Characterization of the immune 
response to Mycoplasma bovis lung infection, is a manuscript published in the journal 
Veterinary Immunology and Immunopathology2. Appendix B, Activation ofWCl+ yôT cells 
by Mycoplasma bovis is consistent with innate immunity, was derived from work presented as 
a poster at the 14th International Congress of the International Organization of 
1 Reprinted with permission of FEMS Immunol. Med. Micro., 2002, (32) pages 97-103 
2 Reprinted with permission of Vet. Immunol. Immunopath., 2003, (94) pages 23-33 
3 
Mycoplasmology (IOM)3. Figures for each chapter are placed within each respective 
chapter. References for each chapter directly follow their respective chapter. 
3 Poster #152, 14th International Congress of the IOM, July 7-12, 2002, Vienna, Austria 
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CHAPTER 2. LITERATURE REVIEW 
1. Mycoplasmas and Disease 
1.1 Introduction to mycoplasmas 
Mycoplasma species belong to the class Mollicutes, the smallest, self-replicating 
organisms known (1,2). The class Mollicutes is phenotypically differentiated from other 
prokaryotes by the lack of a rigid peptidoglycan cellular wall, hence the class moniker 
Mollicutes (molli Latin for soft; and cutis for skin) (2). Due to their limited metabolic 
capabilities, assumed to be a consequence of their small genomes, mycoplasmas exist in 
nature as obligatory parasites, relying on their hosts for growth potential (2). Mycoplasmas 
species are known to colonize humans and animals with extreme host and even tissue 
specificity (2). While some species are commensal organisms, others mycoplasma are 
infectious agents, causing disease in their respective hosts (1,2). 
Mycoplasma species maintain genomes rich in adenine and thymidine. In fact, one of 
the phenotypic characteristics of the genus is a G+C molar percent genomic content of 23 to 
41 (3). In addition, the mycoplasmal genome is relatively small in size (580 to 1,300 kbp) 
compared to other prokaryotes (Escherichia coli genome is 4,640 kbp) (3-5). Mycoplasmal 
genomes have a coding density of approximately 90% (6,7), in comparison to 85% for 
Haemophilus influenza and 88% for E. coli (4, 8). The slight increase in coding density by 
mycoplasmas is most likely due to the increased utilization of operon systems, limiting the 
need for regulatory elements (2, 9). Because of their size and small genomes, it is believed 
that the majority of ORFs code for necessary housekeeping genes, such as Hsp70. Even still, 
a relatively high percent of proteins (approximately 7% of the ORFs) are expressed as 
lipoproteins on the surface of the mycoplasma (based on membrane targeting sequence 
homologies) ((6), Dr. Chris Minion, Iowa State University - personal communication). 
Along with the lipoproteins, mycoplasmas also express non-lipid modified membrane-
associated proteins. These proteins are presumably expressed in high copy numbers as 
membrane-associated protein amounts of some mycoplasma species approaches 44% of the 
total protein content (10). In addition to proteinacious surface molecules, numerous 
mycoplasmas, including the swine, avian, human, and bovine respiratory pathogens, M. 
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hyopneumoniae, M. gallisepticum, M. pneumoniae and M. dispar respectively, are 
encapsulated by highly antigenic polysaccharides (11-15). 
In terms of infectious agents, J.W. Simecka refers to mycoplasmas as, "the most 
under recognized pathogens known today (16)". This is in no way indicative of their 
importance to human and animal health, as up to 30% of all human pneumonia cases are 
reportedly caused by M. pneumoniae (17), and multiple domesticated animals harbor 
infectious mycoplasmas affecting agricultural economics (1,18, 19). In addition to their 
ability to cause disease, mycoplasma infections have also been associated with ailments 
generally considered non-infectious, such as asthma, rheumatoid arthritis, gulf war 
syndrome, tumor formation, and Crohn's disease (20). 
1.2 Innate immunity in mycoplasmal respiratory disease (MRP) 
Innate immune defenses are comprised of physical barriers (mucus), molecular 
defenses (surfactant proteins, lysozyme, and antimicrobial peptides - defensins), and cellular 
defenses (macrophages, neutrophils, and dendritic cells). The role of physical and molecular 
defenses in inhibiting and combating mycoplasmal infections is largely unknown; however, 
the importance of cellular innate immunity in defense against mycoplasmas has repeatedly 
been demonstrated (21). Pathogen loads in SCID (severe combined immunodeficiency) 
mice (mice lacking lymphoid cells) during a M. pulmonis infection are no different than 
those in immunocompetent mice (22). These findings are consistent with lymphoid depleted 
humans infected with M. pneumoniae (23, 24). Corroborating evidence supporting the 
importance of innate immunity in fighting mycoplasmal infections is that the negative 
manipulation of alveolar macrophages in M. pulmonis resistant C57BL/6 mice results in a 
level of infection comparable to susceptible C3H/He mice, linking resistance to macrophage 
activity (25, 26). In addition, reduction of mycoplasmal killing is witnessed in nitrogen 
dioxide exposed mice; this has been directly related to the specific damage of alveolar 
macrophages caused by N02 (27, 28). Surfactant proteins, SP-A and SP-D, molecular 
components of innate immunity, are also important in mycoplasmal infections as these 
proteins increase alveolar macrophages' mycoplasmal killing capacity through induction of 
nitric oxide and ROS (reactive oxygen species) production (29, 30). The induction of ROS 
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and nitric oxide by innate immune cells may affect lymphoid cell activity (discussed in 
section 3.4, endogenous T lymphocyte suppressors). 
Interestingly, alveolar macrophages are the predominant immune cell in combating 
mycoplasmal infection as the increase of PMNs (polymorphonuclear cells - neutrophils) has 
no effect on mycoplasmal clearance (31, 32). The lack of effective clearance by PMNs may 
contribute to the chronic inflammatory state of mycoplasmal infected tissue as PMN 
accumulations are evident during infection (21). The interaction between mycoplasma 
species and innate immune cells generally leads to the production of pro-inflammatory 
cytokines - interleukin-1 (IL-1), IL-6, and TNF-alpha (33-36). In addition to the production 
of IL-1, IL-6, and TNF-alpha, these and other cells (epithelial, fibroblasts, and endothelial -
Dr. Xaodong Lu, Iowa State University, personal communication) also produce chemokines 
(such as MlP-la, MIP1-|3, and ENA-78) in an effort to elicit the help of other innate cells 
and adaptive immune cells (37-44). The chemokines result in the characteristic perivascular 
and peribronchiolar accumulation of mononuclear cells during mycoplasmal respiratory 
infections (discussed later). Other cytokines known to effect adaptive immune responses 
(such as IL-13) can also be produced by cells in contact with mycoplasmas, potentially 
determining the type of adaptive immune response generated during an infection (38). 
Note that the role of dendritic cells (DCs) in combating mycoplasma infections is 
unknown. However, because of immature DC's importance in lymphocyte activation and 
regulation (45,46), these cells may play important roles in lymphocyte directed 
inflammation, respiratory damage, and adaptive immune progression (16,46,47). 
1.3 Adaptive immunity in MRP 
Adaptive immunity, immune reactivity related to lymphoid cells (largely T and B 
cells), can be further broken down into cellular and humoral immunity. These two arms of 
the adaptive immune response work concomitantly to clear pathogens while also establishing 
memory cells to better combat similar or related pathogens if ever re-infected. Humoral 
immunity is traditionally thought of as antibody, or immunoglobulin mediated immunity (B 
cell driven) while cellular responses are traditionally cytotoxic T cell mediated. However, 
since the discovery that activated T helper cells (CP4+ T cells) differentiate into at least 2 
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phenotypically different effector populations (defined by differential cytokine production 
profiles) adaptive immune responses have been re-evaluated in terms of activated T helper 
cell (Th cell) phenotypes (48-50). The two Th effector populations are Thl (T helper type 1) 
cells and Th2 (T helper type 2) cells. The defining differences between the two Th 
populations are the characteristic cytokines produced by each population. Thl cells produce 
cytokines that are indicative of a cellular response such as IL2, a positive regulator of T cell 
development, and IFN-y, a positive regulator of antigen processing. Thl cells are therefore 
associated with cellular immune responses (49, 50). The Th2 phenotype cells produce IL4 
(interleukin 4), IL5, IL 10, and IL13, cytokines that influence B cell development and 
immunoglobulin isotype switching (49, 51, 52); hence the association between Th2 cells and 
humoral immunity. 
The importance of a properly phenotyped response to the invading pathogen has been 
documented in multiple infectious agent models (51, 53-56), the most recognized of which is 
Leishmania major infection. In brief, mice resistant to L. major infection respond to the 
parasite with a Thl type response while susceptible mice generate a Th2 response upon 
infection (55, 57-59). The production of antigen-specific antibodies via reactive B cells 
occurs in both Thl and Th2 characteristic immune responses. The difference in Ig-
production between these two types of responses is the isotype of antibody produced (52). 
The differences in isotype can have a substantial effect on disease progression as some 
antibody isotypes are more proficient at complement activation, opsonization, or innate 
immune cell activation (60, 61). While the phenotype of a protective response to 
mycoplasmal infection is not known, multiple studies suggest that mycoplasmal infection 
induces a Th2 type response (62-68). This connection has been suggested as a role for 
mycoplasmal agents in increasing the incidence of asthma or airway allergies (63, 66), as 
Th2 responses in the respiratory tract are known to contribute to these types of diseases (69-
75). 
In terms of T and B cell responsiveness, both are activated during mycoplasmal 
infection (16, 67, 76, 77). Early studies indicated an influx of mononuclear cells, which 
included T and B cells, into the lungs and lung draining lymph nodes of mycoplasma infected 
animals (78-81). These immunohistochemical observations indicate an activation of adaptive 
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immune cells based on cellular trafficking and active antibody production by B cells located 
in infected lungs (79, 82). The importance of adaptive immunity has been documented in the 
protection against select mycoplasmal infectious diseases through vaccination (83-86). The 
contribution of each type of response (cellular vs. humoral) in protection however, may vary 
from species to species as humoral responses are sufficient to protect mice against M, 
pulmonis infection (87), while passive transfer of immune cells but not sera is able to protect 
rats against M. pulmonis infection (88). As discussed earlier, the innate immune system is 
important for the clearance of respiratory mycoplasmas, however, the infection of T cell 
deficient mice with M. pulmonis leads to an increase in arthritis severity compared to mice 
with normal T cell numbers (16, 89). Experimental lung infection of SCID mice (mice 
lacking both T and B cells) with M. pulmonis leads to severe, disseminating disease causing 
both MRD and arthritis (22, 90) while not effecting the pathogen load (discussed earlier). 
The passive transfer of immune sera to infected SCID mice is sufficient to limit the systemic 
spread of the mycoplasma, therefore limiting clinical symptoms of arthritis (22). This 
suggests that the observations, in T cell deficient mice were possibly due to the lack of B cell 
activation by T helper cells. The findings demonstrate the importance of antibody responses 
in limiting the dissemination of infectious mycoplasmas and are consistent with clinical 
observations of hypogammaglobulinemic patients infected with M. pneumoniae, who show 
persistence of clinical symptoms as well as increased incidence of multi-organ infection, 
despite having normal T cell counts (91, 92). Individuals suffering from T cell deficiencies 
do not experience increased susceptibility to M. pneumoniae infection as do 
hypogammaglobulinemic patients (21,23). These observations highlight the importance of 
humoral responses in combating mycoplasma infections. 
Cellular responses, however, are also important in protection against some 
mycoplasmal disease conditions as passive transfer of mycoplasma specific mononuclear 
cells into mycoplasma infected rats decreases severity of disease while passive antibody 
transfer has no effect (88). Despite the apparent effectiveness of immune responses in 
combating mycoplasmal infections, very few mycoplasmal vaccines are licensed for use. 
The lack of success in creating mycoplasmal vaccines can be attributed to duration of 
immune protection (acquired immunity to mycoplasmas is short-lived (16)), and that many 
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vaccine attempts have simply decreased infectious agent loads and did not deter colonization 
or infection (16, 86, 93, 94). 
It is well accepted that immunological responses to respiratory mycoplasmal infection 
play a role in disease pathogenesis through induction, production, and maintenance of 
inflammatory mediators (16). The most incriminating studies consistently show a decrease 
in lung lesion size and severity in animals treated with immunosuppressive therapies (22, 89, 
90, 95). Reconstitution of T cells in infected, immunocompromised animals results in an 
increase in lung lesion size and severity (22, 96). Delineating the importance of individual 
immune cells and regulators in disease progression is currently an active area of 
mycoplasmal research (96). Despite the damage induced by an immune reaction to 
mycoplasmal infection, however, it has been demonstrated that immunological responses are 
important in protecting against or reducing the severity of clinical disease (16). The 
complexity of host immune cells and mycoplasma interactions is compounded by the fact 
that multiple mycoplasmal species are able to directly or indirectly modulate immune cell 
responses (discussed later). 
2. Mycoplasma bovis 
2.1 Introduction to Mycoplasma bovis 
The bovine pathogen Mycoplasma bovis is one of more than twenty mycoplasmas 
known to colonize cattle (97); and is responsible for multiple diseases in cattle, including 
pneumonia, mastitis, arthritis, otitis, conjunctivitis, decubital abscesses, and urogenital tract 
infections (97-102). In addition, M. bovis has been cultured from brain, spinal cord, nerve 
endings, bull semen, and from the abomasal (4th stomach) contents of an aborted calf (99, 
103, 104). While predominantly considered an agent of mastitis, pneumonia, and arthritis, 
isolation of M. bovis from other, non-related, organs (as described) has been cited as proof of 
systemic capabilities (97). 
Mycoplasma bovis was first described under the name Mycoplasma agalactiae 
mastitidis isolated in 1961 from a bovine mastitis infection (105). Between 1962 and 1976 
the pathogen was referred to as either M. agalactiae subspecies bovis (97) (owing to its 
antigenic and pathological similarities to the goat pathogen M. agalactiae (97), or 
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Mycoplasma bovimastitidis (106), until an official species assignment of M. bovis in 1976 
(107). Since its discovery, M. bovis has been isolated from animals in a number of countries 
(108); and, while not ubiquitous, is considered to have world-wide distribution (97, 108). In 
addition to its distribution, the number of outbreaks and/or infected herds in endemic areas 
appears to be on the rise (109,110). 
As a pathogen of both respiratory tract and mammary glands, M. bovis is responsible 
for substantial economic losses in both beef and dairy industries (18, 19). The severity of a 
herd infection is compounded by a non-responsiveness of infected animals to antibiotic 
treatment (108). Lacking a cell wall, mycoplasmas are inherently resistant to antibiotics that 
target cell wall construction (e.g. penicillin, ampicillin, oxacillin). Other antibiotics targeting 
prokaryotic ribosome function or DNA gyrases, such as tylocin, lincomycin, oxytetracycline, 
and enrofloxacin, have shown inhibitory effects on M. bovis growth in vitro; however, these 
therapeutic agents are not effective in combating infections (97). Due to the ineffectiveness 
of current treatment strategies, developing an effective vaccine, as a preventive measure 
against M. bovis, is an active area of research. 
Compared to other mycoplasma species, M. bovis has an average sized genome 1,080 
kbp (Mycoplasma spp. genome size range 600kbp - 1350kbp) maintaining a G + C ratio of 
27.8-32.9 mol% (Mycoplasma spp. G + C ratio range 23-40%) (108,111). Due to its limited 
metabolic capabilities (2), M. bovis is commonly grown in highly enriched media based on 
Friis formulations (112). This media contains a high level of serum, necessary to fulfill M. 
bovis's requirement of cholesterol for growth, as serum lipoproteins have been shown to be a 
cholesterol source for mycoplasmas (113-115). This requirement may have implications in 
understanding changes in cell physiology and/or function upon interaction with mycoplasma 
species, as cholesterol is an important component of cellular lipid bilayers. 
Like other mycoplasmas, M. bovis is extremely host-specific being isolated primarily 
from domesticated bovine species. This concept of a limited host range may be a 
consequence of limited research into other large ruminants as M. bovis has been isolated 
from respiratory tract of pneumonic American bison (Dr. Ricardo F. Rosenbusch, Iowa State 
University - personal communication)(108), and has been demonstrated to colonize sheep 
that are in contact with infected cattle (97). Infected sheep however, do not show clinical 
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signs of disease and are therefore considered a possible reservoir (97). There has also been 
one published case of M. bovis being isolated from a woman suffering from 
bronchopneumonia (116). While the natural susceptibility of non-bovine hosts to M. bovis is 
unclear, experimental models of M. bovis disease have been successful in sheep, mice, 
rabbits, and goats (97, 117-120). 
2.2 Variable surface proteins (Vsp) 
Chronicity is a common characteristic of M. bovis infections, shared by most 
infectious mycoplasmas (97, 121). M. bovis has been isolated from animals for months to 
years following clinical disease (97). While the factors responsible for mycoplasmal 
chronicity may vary depending upon species and encompass a number of mechanisms, 
evading the immune system is paramount for mycoplasmal persistence within the host (122). 
Phenotypic plasticity is one immune evasion mechanism used by mycoplasmas that has 
received attention (122). The plasticity in phenotype is a result of altering surface antigens 
on the mycoplasma. This phenomenon of antigenic variation, also seen in other bacteria and 
parasites, presumably renders adaptive immune responses ineffective against heterogeneous 
populations of mycoplasmas during an infection. The basis of mycoplasmal antigenic 
variation is the maintenance of surface proteins that can be altered in structure or expression 
(123-129). Families of these variable proteins have been identified in multiple mycoplasma 
species (2, 130, 131) including the respiratory pathogens M. pulmonis, M. agalactiae, M. 
gallisepticum, and M. bovis (125, 127,132). The family of alterable surface proteins 
encoded for by the M. bovis genome are called variable surface proteins or Vsp's (133). The 
Vsp family of proteins contains 13 members (133). While this group is the most studied of 
the M. bovis variable proteins, others do exist (134) (Anthony Vanden Bush, Dr. 
Rosenbusch's laboratory, Iowa State University - lab observation). 
The Vsp proteins of M. bovis share 2 basic characteristics: 1) a homologous N-
terminus highly conserved as a lipoprotein signal peptide (133) and 2) a unique internal 
sequence characterized by multiple amino acid repeat regions. The first 25 amino acids of the 
N-terminus are highly conserved (99%) between Vsp family members as this region encodes 
the lipoprotein signal peptide, therefore, targeting the mature protein to the cell membrane 
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post-modification (133,135). The 25th amino acid residue, Cys, is 100% conserved (125, 
133). This Cys residue is acylated and subsequently responsible for anchorage of the mature 
lipoprotein to the cell membrane (133). 
The variability between family members is within repeat domains contained in the 
internal portion of the protein. These domains are generally comprised of amino acid 
sequence units repeated in tandem (125, 133). These repetitive units vary in amino acid 
sequence and length, and may occur in more than one Vsp family member. For example, the 
first repetitive unit found in VspA, the hexamer -PGENKT (denoted RA1, for repeat #1 of 
Vsp A protein), is present as 10 tandem repeats in VspA, 5 tandem repeats in VspG, and 8 
tandem repeats in VspH. In contrast, VspO contains 12 repeats of RA1 distributed in two 
distinct locations (11 tandem repeats and one hexamer unit that stands alone). In all, 18 
distinct repeat regions have been identified, comprised of 6, 8,10,11,12, 26, 84, or 87 
amino acids (133). 
The variability in the expression pattern of Vsp family members can occur via three 
recombinatory mechanisms, 1) the expression of one gene is 'turned off while another is 
'turned on', 2) one gene is 'turned off without inducing expression of a second gene, and 3) 
recombination of two genes leading to the expression of an unique gene product (136). 
These events can occur through high frequency, site specific inversions or recombinations 
(possibly driven by site specific recombinases or through spontaneous mutations of 
regulatory '5 nucleotide regions such as promoters (127,136-139). Interestingly, in addition 
to the identification of a M. bovis site specific recombinase (138), there exist 2 regions of the 
vsp loci that encode sequences homologous to known 'moveable genetic elements' (133). 
The hypothesis that Vsp modulation is a mechanism of immune evasion by M. bovis 
is validated by the high antigenicity of Vsp family members (140) (if these proteins were not 
antigenic they would not make good decoys) and that incubation of VspA+ M. bovis with 
anti-VspA antibodies triggers phenotypic changes in Vsp expression (121), i.e. VspA is 
turned off. In addition, contact between M. bovis and bovine macrophages also triggers 
changes in Vsp expression (141). It is important to note that, to date, only a few members of 
the Vsp family demonstrate expression (140). The majority of Vsps, for example VspL, 
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currently exist as tentative gene products based on sequences characteristic of open reading 
frames. 
In conjunction with the passive immune evasion function, Vsps are known to play an 
active role in cellular adhesion (140,142-144). Specific Vsp members appear to have 
stronger affinities for cellular adhesion than others, based on their repetitive epitopes (140). 
While the affinity of individual Vsps for cellular adhesion may differ, it appears that their 
role in adherence is largely ubiquitous among Vsp family members (140, 142-144). This 
redundancy in adhesion ability is important due to the variability in Vsp expression; if one 
Vsp is down regulated or turned off, adhesion is not affected. Despite intense study, no 
additional function for any Vsp family member has been demonstrated to date. 
2.3 Immune Response to Mycoplasma bovis 
Immune responses to M. bovis infection are of particular interest as it is generally 
accepted that tissue damage (lung lesions) characteristic of respiratory mycoplasmal infection 
are, in part, due to the immune response (discussed earlier). Early evidence supporting 
immunpathogenesis in M. bovis infections includes the accumulation of lymphocytes in 
peribronchiolar and perivascular space, as with other mycoplasmal respiratory infections (76, 
81). However, in M. bovis infections, accumulations of lymphoid cells surrounding the lung 
lesions (macroscopic focal regions of coagulative necrosis) are the primary inducers of 
increased lung pathology, and not the peribronchiolar and perivascular lymphocyte 
accumulations (76, 80, 81). This is in contrast to other mycoplasma respiratory infections 
(82, 145). More recently, the hypothesis of immune response involvement in lung damage 
has been upheld by a phenomenon known as vaccine induced susceptibility (VIS) or 
'priming' (146,147). VIS is defined as an increased amount of lung damage in vaccinated 
animals following challenge when compared to challenged/non-vaccinated control animals. 
While a recently developed M. bovis vaccine is purported not to lead to VIS (148), other 
vaccine strategies have routinely led to VIS (Dr. Ricardo Rosenbusch, Iowa State University 
- lab observation). The VIS phenomenon is consistent with adaptive immune response 
involvement in lung damage. Further evidence of immune mediated lung damage in 
mycoplasmal disease has been demonstrated in the mouse MRD model of M. pulmonis 
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infection (discussed earlier). Regardless of the roles T cells play in tissue damage, it is 
known that both adaptive and innate immune responses are important in protection against 
mycoplasmal infections (16, 21, 22). 
Mycoplasma spp. have routinely been shown to activate cells of the innate immune 
system (21,149-151). In particular, M. fermentons has been shown to activate monocytes via 
interaction with Toll-like receptor 2 (152,153). Incubation of M. bovis with alveolar 
macrophages induces the production of NO and TNF-alpha, two potent mediators of immune 
activity, by the alveolar macrophages (149). Antigens derived from M. bovis have also been 
shown to activate bovine yô-T cells in vitro, in a manner consistent with innate immunity 
(67). While T cells are traditionally thought of as adaptive immune cells, peripheral yô-T 
cells in cattle are known to bepome activated in a manner consistent with innate immunity 
(e.g. as with mycobacterial antigens (154,155)) and are able to present antigen to Th cells 
(156). The in vivo role of bovine yô-T cells in innate immunity has yet to be elucidated. 
While the activation of innate immune cells by M. bovis has been documented, it is currently 
unknown if toll-like receptors (TLRs) are involved in this activation. In contrast to 
macrophages, neutrophils appear to be inhibited by M. bovis (this will be discussed in a later 
section) (157). Following an initial response of innate cells during a M. bovis infection, 
adaptive immune cells are educated in order to mount a response toward M. bovis. 
Adaptive immune responses to M. bovis are measurable by blastogenesis and/or 
serological assays; however, the level of proliferative response (blastogenesis) to M. bovis 
antigen is not very pronounced (67,158) and in some studies has been lacking completely 
(159). Because of this, and the ease of serological study, serology has generally been used to 
measure adaptive immune responses to M. bovis (158, 160). 
Studying both peripheral lymphocytes and serum during a M. bovis infection it was 
determined that the immune response to M. bovis lung infection is skewed towards a type 2 
immune response (classically considered a humoral response) (67). Consistent with 
serological studies, immunohistochemical studies indicate a large number of IgGl producing 
cells (IgGl is an indication of a Th-2 response (49)) in the lungs of infected cattle (76). 
Despite the activity of both innate and adaptive immune cells, M. bovis tends to persist as a 
chronic infection, with organisms being recovered from post clinical animals up to several 
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months (97). It has been hypothesized that one contributing factor to the chronicity of a M. 
bovis infection is that the serological response may not be of the correct phenotype as IgG2 
and IgM are superior opsonins compared to IgGl (60). In addition, IgGl is an inferior 
activator of complement compared to other IgG isoforms (61). 
3. Lymphocyte Function and Suppression 
3.1 T lymphocyte activation 
This section is designed to give an overview of T cell activation by TCR engagement 
and mitogenic stimulation, followed by the description of T cell suppression by multiple 
compounds and their generally accepted mechanisms of lympho-suppression. These 
compounds have been divided into groups based largely on origin and molecular makeup. 
These groups include, endogenous lymphocyte inhibitors, immunosuppressive drugs, 
immunosuppressive peptides, bacterial products that inhibit lymphocyte activity, and 
mycoplasma induced immunosuppression. Following this portion is a brief description of 
apoptosis and its importance to lymphocyte homeostasis and pathogen induced lymphocyte 
suppression. 
Lymphocytes, a group of cells making up the adaptive portion of an immune system, 
largely consist of B and T cells. Activation of these cells occurs through engagement of 
respective activating receptors (T cell receptor - TCR, and B cell receptor BCR) with their 
respective ligands (161-163). In the case of T cells, the TCR is a heterodimer consisting of 
either a and |3 subunits (a|3 TCR) or y and ô subunits (yÔ TCR) (162, 164). The ligand for 
the TCR is an MHC: peptide complex presented on either target cells (any nucleated cell -
MHC class I) or antigen presenting cells (macrophages, B-cells, dendritic cells - cells of the 
innate immune system, MHC class II) (161). On the T cell's surface, the TCR complex is 
further associated with the hetero-hexamer CD3 (165). For naïve mature T cells the CD3 
multimer is responsible for signal transduction perpetuated by TCR: ligand engagement (165, 
166). Following TCR engagement, phosphorylation cascades are induced that ultimately 
lead to T cell activation (162, 167). Interruption of key signal transduction events will 
effectively inhibit T cell activation (proliferation, differentiation, and/or cytokine production) 
and therefore retard an effective immune response (168, 169). T cell activation can be 
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experimentally mimicked in vitro by engaging the CD3 with antagonizing antibodies or by 
the addition of lectin mitogens, such as concavalin A (ConA), phytohemagglutinin (PHA), or 
pokeweed mitogen (PWM) in the presence of APCs (antigen presenting cells). Although 
there is a difference in cytokine production between signals generated by TCR engagement 
and those induced by mitogen contact, the majority of intracellular signaling events (PLC-y 
activation, Ca2+ influx, calcineurin activation, MAP kinase cascades, etc.. .)(170-172) are 
similar. The extent to which mitogen-stimulated T cells undergo CD3 hyperphosphorylation 
is unknown, however, the phosphorylation of the Src kinase Lck (involved in CD3 
phosphorylation) is necessary for PHA induced maturation of T cells, presumably through an 
undefined interaction between Lck and MAP kinase pathways (173). 
3.2 TCR signaling 
Initially the interaction between TCR and MHC:peptide leads to a morphological 
rearrangement of lipid domains maintained in the T cell's lipid bilayer known as rafts (174). 
During T cell activation (i.e. TCR and MHC:peptide engagement), TCRs and positive 
regulators of T cell signaling are found associated with rafts (174-176). Raft maintenance 
and formation, is dependent upon cholesterol (177); and, presumably, so too is cell signaling 
and T cell activation (174,178). This may be important in understanding the effects of some 
mycoplasmas (cholesterol sequestering organisms (113-115, 179) on lymphocyte 
functionality (section 3.8). 
If raft formation is uninterrupted upon TCR engagement, cytoplasmic domains of 
CD3 known as ITAMS (immunoreceptor tyrosine-based activation motifs) are 
phosphorylated by non-receptor tyrosine kinases (162,165,180). The IT AM motifs contain 
multiple phophorylatable tyrosine residues. These phosphorylated tyrosines serve as 'docking 
sites' for a group of kinases containing phosphorylated tyrosine binding domains (180, 181). 
These domains are called SH2 (Src homology 2) domains after the protein kinase, Src (181). 
The kinases, aptly named Src family kinases, propagate and expand the signaling cascades 
initiated by TCR engagement (180,182). 
As with any cell, receptor induced responses are dependent on the coordination of 
intracellular signaling events. The phosphorylation cascades that are initiated by TCR 
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engagement are responsible for the T cell's differentiation into a mature, activated T effector 
cell, but not before these cascades have branched out to effect other necessary components of 
T cell activation, such as calcium influx (183). Phosphorylation cascades in the activation of 
T cells are linked to calcium flux via the activation of LAT (linker of activation in T cells) 
(165, 184, 185). LAT is a membrane bound tyrosine kinase activated downstream from CD3 
IT AM phosphorylation following TCR engagement. The activation of LAT subsequently 
leads to the activation of the phospholipase-C gamma 1 (PLCyl) Ca2+ pathway (184). The 
activation of PLCy leads to the cleavage of phosphatidylinositol 4,5-bisphosphate to 
diacylglycerol and inositol 1,4,5-triphosphate (IP3)(183). IP3 binds to its receptor on the 
endoplasmic reticulum (ER), ultimately leading to the release of intracellular Ca2+ stores 
from the ER (183). This release increases the level of cytoplasmic Ca2+, and induces the 
opening of membrane Ca2+ channels, known as CRAC channels (calcium release activated 
calcium channels), which allow the influx of external Ca2+ (183, 186). A sustained Ca2+ 
current is necessary for T cell activation (183), and is achieved by K+ channels/pumps used to 
maintain membrane hyperpolarization (187) (this is important in understanding the effects of 
some K+ pump inhibitors on T cell activation - discussed later). The dependency of T cell 
activation on Ca2+ influx is due to its indirect role in gene transcription (187). 
The transcription of genes in T cells, as in all cells, is dependent upon the activation 
of transcription factors and regulators. An important transcription factor in T cells is known 
as nuclear factor of activated T cells or NFAT (of which there are multiple family members) 
(188). In its inactive state NFAT is phosphorylated and held within the cytoplasm (188, 
189). Upon dephosphorylation, NFAT is translocated to the nucleus and augments 
transcriptional regulation of target genes such as IL-2 (190), an important cytokine with 
positive feedback effects on T cell activation/proliferation (191, 192). The 
activation/dephosphorylation of NFAT is catalyzed by the Ca2+ dependent phosphatase 
calcineurin (193), therefore linking Ca2+ influx and phosphorylation events to gene 
transcription and T cell activation. Calcineurin is thought to be the link between Ca2+ flux 
and regulation of gene transcription in multiple pathways, but is extremely important in T 
cell activation as blocking its activity abrogates TCR mediated T cell activation (194-196). 
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3.3 Immunosuppressive Drugs 
Immunosuppressive compounds are commonly divided into 5 groups based on 
suppressive mechanisms (Table 1). Glucocorticoids are the model drug for Group 1, 
regulators of gene expression (Table 1). The use of glucocorticosteroids in treating 
autoimmune disease and their mechanisms in lymphocyte suppression will be covered briefly 
in a later section dedicated to endogenous lymphocyte suppressors (pages 21-23). 
Groups 2, 3, and 4, from Table 1, specifically target nucleic acids in their mechanisms 
of immune suppression (168). Cyclophosphamide (Cy) is an alkylation model drug (group 
2), that chemically modifies genomic DNA, subsequently suppressing cell division as its 
primary mechanism of therapeutic action (168, 197). Cyclophosphamide major effect is seen 
in suppression of antibody production (197), while the reasons for Cy's preferential 
suppression of B cell responses vs. T cell responses is unknown. Cyclophosphamide is 
therefore used in cases of antibody dependent autoimmune diseases such as systemic lupus 
erythematosus (168). However, the use of Cy increases the risk of cancer due to its 
modification of DNA (168). . 
Table 1. Mechanisms of immunosuppressive drug action 
General Mechanism of action Drug 
1. Regulation of gene expression Glucocorticoids 
2. Alkylation Cyclophosphamide 
3. De novo pyrimidine synthesis inhibition Methotrexate 
Leflunomide 
4. De novo purine synthesis inhibition Azathioprine 
Methotrexate 
5. Kinase/Phosphatase inhibition Cyclosporin A 
Tacrolimus (FK506) 
Rapamycin 
p38 kinase inhibitors 
Adapted from: Anthony C. Allison, 2000, Immunosuppressive drugs: the first 50 years and a 
glance forward, Immunopharm, 47, page 64. 
Groups 3 and 4 are inhibitors of pyrimidine and purine de novo synthesis 
respectively. These compounds halt effective production of nucleic acids needed for cellular 
division and general cell functions (168,198). Because of their mode of action, these drugs 
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have the most effect on nucleotide dependent cells, such as blastogenic lymphocytes (rapidly 
dividing cells). The first immunosuppressive drug targeting purine synthesis was 
Azathioprine (AZA) (199), a compound that is metabolically converted to the purine 
homolog, 6-thioguaninenucleotide (200). This metabolite of AZA is an inhibitor of multiple 
enzymes involved in purine synthesis including PRPP-aminotransferase and 
adenylosuccinate synthase (201). Other metabolite derivatives of AZA also aid in 
lymphocyte inhibition, depleting lymphocytes of adenosine and guanine nucleotides (198). 
Methotrexate (MTX), a drug originally designed to treat malignancies (168, 202), is a 
folate antagonist routinely used in treating rheumatoid arthritis. The mechanism of MTX 
therapeutic effects is attributed to its blockage of purine and pyrimidine de novo synthesis. 
The mechanism involved in blpcking de novo pyrimidine synthesis is the inhibition of 
dihydrofolate reductase. This enzyme is responsible for the conversion of dihydrofolate to 
tetrahydrofolate. Tetrahydrofolate is in turn used by thymidylate synthase to convert dUMP 
to dTMP. Subsequently the use of MTX results in a shortage of dTTP used in DNA 
synthesis (168, 203). The inhibition of purine synthesis is believed to be through the 
inhibition of other folate-dependent enzymes such as AICAR (5 -amino-imidizole 
carboxamide ribonucleotide) transformylase (203). This enzyme is responsible for the 
completion of purine de novo synthesis. Additional mechanisms may be utilized by MTX as 
administration of folic acid, shown to overcome the depletion of tetrahydrofolate, abrogates 
the side effects associated with MTX, but does not alter the therapeutic effects (204, 205). 
One addition to MTX suppressive capabilities is the induction of apoptosis in activated 
lymphocytes (206). 
While no mycoplasmal products that are able to modify host DNA or inhibit 
purine/pyrimidine synthesis have been identified, multiple mycoplasmas have been shown to 
produce unique DNases able to digest host cell DNA (207-211). Presumably these DNases 
could induce apoptosis of host cells, including lymphocytes (209, 211); however, the 
identification of mycoplasmal DNases in apoptotic cells has only been realized when in vitro 
cell cultures contaminated with mycoplasmas were experimentally induced to undergo 
apoptosis (209, 210). Therefore a cause and effect relationship between mycoplasmal 
DNases and host cell apoptosis is lacking. 
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The final group of immunosuppressive drugs, Group 5, is the inhibitors of kinase and 
phosphatase activity. Due to the complex signaling cascades generated during the activation 
of T cells, kinase and phosphatase inhibitors are effective immunosuppressants. Many 
compounds have been identified as potential drugs based on their ability to suppress specific 
phosphorylation dependent pathways, such as the MAP kinase pathway (169). Two of the 
most often used immunosuppressive drugs in this group (kinase/phosphatase inhibitors) are 
Cyclosporin A (CsA) and Tacrolimus (FK506). Unlike the inhibitors of MAP kinase 
pathway, these drugs inhibit signaling cascades at a critical point of phosphatase and calcium 
dependent activities (187). 
Cyclosporin A and FK506 both form complexes with heterogeneous binding proteins 
(immunophillins) known as cyclophillins and FK506 binding proteins, respectively (187, 
212). Once engaged with cyclophillin (CsA/CP) and FKBP (FK506/FKBP) these complexes 
are each able to bind to and inhibit calcineurin's phosphatase activity (212), therefore 
inhibiting nuclear translocation of NFAT transcription factors (187, 212). Due to their 
effects on calcineurin, these compounds are grouped in kinase/phosphatase inhibitors but are 
classified specifically as calcineurin inhibitors (168). It has recently been hypothesized that 
the binding of these complexes to calcineurin may invoke their NFAT suppressive activities 
via additional means. The complexes may block the co-transnuclear location of CN allowing 
the re-phosphorylation of NFAT by nuclear kinases subsequently leading to NFAT being 
shuttled out of the nucleus (213). In addition to the inhibition of NFAT translocation, CsA 
has been shown to block additional phosphorylation pathways such as janus kinase (INK) 
and p38, two important signaling pathways in T cells (214). 
Additional mechanisms* outside the 5 described groups of immunosuppressive drugs, 
have been described, including the induction of T cell apoptosis (168), and modulation of T 
cell peripheral mobility (215). Interestingly, multiple drugs posses more than one functional 
activity. For example, CsA is described as an inhibitor of calcineurin, but also induces the 
production of TGF-|3 by lymphocytes (168,216). The production of this immune regulatory 
cytokine (section 3.4) is blamed for multiple side effects of CsA administration, but may also 
contribute to its lympho-suppressive attributes, as TGF-J3 is a known T cell regulator (217-
219). The induction of a regulatory cytokine to control immune responses is an effective 
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strategy in immunotherapy as demonstrated by KM2210. KM2210 is a immunosuppressant 
whose mechanism of action is the induction of immmuno-regulatory cytokines IL-10 and 
TGF-p (220). 
3.4 Endogenous T lymphocyte suppressors 
The following is a brief description of compounds that are able to suppress 
lymphocyte functions. This is not intended to be an exhaustive discussion of known 
endogenous T lymphocyte suppressors. 
Glucocorticosteroids, such as cortisone, were the first group of endogenous 
compounds shown to be immune modulatory through their beneficial medicinal effects on 
diseases such as arthritis and asthma (221, 222). Further studies illustrated the usefulness of 
these compounds in preventing allograft rejection and treating immune disorders (168). The 
primary mechanism of lymphocyte inhibition by glucocorticosteroids is the negative 
regulation of immune regulatory genes such as IL-2 (168, 223). In addition to gene 
regulation, glucocorticosteroids have also been implicated in posttranslational mechanisms of 
immune modulation, for instance, decreasing mRNA stability (224) and inducing apoptosis 
of cells by disrupting mitochondrial membrane potentials (225). Other steroids and opoids, 
such as beta-endorphin and met-enkephalin, have modulatory effects on lymphocyte function 
as well (226, 227). Gonadal steroids have received most of the attention due to the gender 
differences in immune system functionality (226, 228-230). In general, it is said that 
estrogens enhance immune function while androgens suppress immune function (226). 
However, these effects have proven to be dose dependent as homeostatic levels of estrogens 
are shown to be immunosuppressive. As revealed by Simecka et al., these differences in 
gender steroids may play a direct role in mycoplasmal respiratory infections as male mice are 
more susceptibility to M. pulmonis MRD than female mice (231). 
While the production of specific steroids or hormones may have a purposeful effect 
on lymphocytes, their production is generally associated with other non-immune biological 
functions. In some instances immune modulating biomolecules are produced specifically to 
control or 'tamp down' immune responses. During pregnancy, for example, EPFs (early 
pregnancy factors) are produced by the pregnant female (232). These serum proteins are able 
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to inhibit T cell function in vivo by down regulating adhesion molecules (VCAM-1, ICAM-
1, and integrins LFA-1, VLA4, and MAC1) necessary for T cell tissue migration (232, 233). 
The up-regulation of EPFs therefore inhibits T-cell functionality in vivo by blocking 
extravasation, and potentially limits immune recognition of the fetus. 
Other mechanisms of endogenous suppression are dependent upon immune tissues or 
cells themselves. The majority of these suppressive interactions are based on secreted factors 
such as cytokines. The microenvironment of Peyer's patches, gut associated lymphoid tissue 
located in the ileum of the small intestine, naturally suppresses T cell proliferation. The 
suppression was due to secreted factors. It was further suggested that the suppressive 
environment of the Peyer's patches was due to its Th2 cytokine phenotype, as the researchers 
failed to identify a single factor responsible for the suppressive effects (234). 
It is also possible for ROS (reactive oxygen species) to inhibit T cell function. The 
source of which may be APC, innate immune cells, or the T cells themselves (235). It is 
believed that ROS may suppress T cell function by two mechanisms. The first is through the 
induction of apoptosis as peroxide induces the expression of the proapoptotic ligand, FasL 
(236-239) and decreases the expression of BcL-2 anti-apoptotic family members (240, 241). 
The second is through the misregulation of redox potentials and their effects on transcription 
factors and gene regulation (242,243). The difference between inhibition and apoptosis 
induction by ROS is thought to be dose dependent (243). 
One of the most recognized endogenous T cell suppressors is TGF-J3 (transforming 
growth factor beta). TGF-p is a cytokine associated with adaptive immune system regulatory 
functions (244, 245). TGF-|3 can be produced by a number of cells including, macrophages, 
neutrophils, dendritic cells, and T lymphocytes under various conditions (246, 247). While 
normally considered a negative regulator of lymphocyte function, TGF-(3 has been shown to 
act as a positive regulator of T cell function at low concentrations (0.1-lpg/ml) (219). In 
terms of negative regulation, TGF-|3 has been implicated in the down-regulation of IL-2 
production, IL-2R alpha production, inhibition of tyrosine phosphorylation of specific 
Jak/Stat family members and a decrease in antigen induced T cell proliferation (219, 248, 
249). TGF-|3 has also been shown to aid in induction of T cell apoptotic milieu (246, 249). 
The importance of TGF-|3 in lympho-proliferation and as a T cell regulator has been 
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demonstrated in multiple studies. For example, the loss of TGF-|3 receptor expression 
described in T cell malignancies (250), the correlation between TGF-J3 serum levels and 
posttraumatic immunosuppression (251), and TGF-|3 expression by CD4+CD25+ regulatory T 
cells (Treg) as a membrane bound cytokine (252). In fact, the Treg inhibitory effects on T cell 
proliferation are significantly modulated by the addition of anti-TGF-(3 antibodies (253). 
Interestingly, the production of TGF-(3 is also reported to be a mechanism utilized by some 
pathogens to dampen immune responses (discussed below) (254, 255). 
3.5 Lymphocyte apoptosis 
While inhibiting T cell differentiation will suppress an adaptive response, depletion of 
T cells will also suppress adaptive immunity. As a safeguard against uncontrolled 
proliferation, cells are equipped with means of suicide or programmed cell death (apoptosis). 
While apoptotic mechanisms ar,e, often discussed in terms of removing pre-cancerous cells, 
these mechanisms are also used in homeostatic maintenance of lymphocytes (256). Upon 
activation, T cells undergo clonal expansion in order to increase the numbers of antigen 
specific cells to fight infection (239). After the peak of initial T cell expansion, T cell 
numbers begin to decline. This phenomenon is referred to as contracting and often occurs 
prior to pathogen clearance (257). Contraction is a result of mass apoptosis via two 
mechanisms, AICD (activation induced cell death) and ACAD (activated T cell autonomous 
death) (235). AICD is controlled by exogenous signals delivered to the T cell, generally via 
interaction of membrane bound death receptors Fas (CD95) and/or TNF-alphaR with the 
respective ligands, FasL and TNF-a (235). In contrast ACAD, is controlled through intrinsic 
T cell signals, mediated by differential regulation/activation of Bcl-2 (pro and anti-apoptotic 
family of proteins) related proteins (235). Reactive oxygen species, NO, and TGF-|3 have 
been implicated in both forms of apoptosis (235, 239, 258). Again, some pathogens have 
been shown to induce the apoptosis of T lymphocytes as a possible mechanism of immune 
evasion. This is discussed in section 3.7, 'Bacterial products modulating lymphocyte 
responses'. 
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3.6 Immunosuppressive Peptides 
A number of peptide toxins isolated from marine invertebrates and arachnids have 
been shown to inhibit T lymphocytes in vitro (259-265). These peptides share structural 
features while having little amino acid sequence homology with one another. The structural 
feature shared by these peptides is the conservation of 6 cystine residues that are involved in 
forming 3 di-sulfide bridges (266-269). As these peptides are usually no longer than 40 
amino acids, these 3 bridges impose a great deal of stability and rigidity to these peptide 
structures. 
This structural motif is also found in (3-defensins, anti-microbial peptides secreted by 
a number of mammalian cells including mucosal epithelia (270-272). Unlike the |3-
defensins, however, these toxin peptides bind to and inhibit K+ selective proton pumps 
expressed on T cells (273). This binding renders the pump non-functional, subsequently 
affecting Ca2+ influx patterns (discussed earlier). These peptides therefore block Ca2+ 
dependent signaling events and inhibit the activation of the prospective T cell. The use of 
these peptides as immunosuppressant drugs is currently being tested and showing promising 
results in EAE (experimental autoimmune encephalitis), a mouse model of multiple sclerosis 
(260,263). 
Not all immunosuppressive peptides are K+ ion pump inhibitors. For example, the 
drug cyclosporin A (section 3.3) is a cyclic undeca-peptide inhibitor of calcineurin (274). An 
antimicrobial cecropin-like peptide produced by Helicobacter pylori has homology with 
members of the cecropin family (anti-microbial peptides produced by insects (275)) and is 
also able to suppress lymphocytes. The H. pylori cecropin-like peptide is an alpha-helical 
peptide, and does not contain any cystine residues, in contrast to the peptide toxins 
mentioned above. This peptide suppresses lymphocytes through an indirect mechanism, 
involving the activation of monocytes (discussed below). 
3.7 Bacterial products modulating lymphocyte responses 
Suppression of lymphocyte responses is a mechanism of immune evasion utilized by 
several microbial pathogens (276, 277). Suppressive mechanisms utilized by bacterial 
pathogens can largely be divided into 2 categories, 1) direct suppression of lymphocytes, and 
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2) lympho-suppression mediated by microbe-induced innate immune cells (macrophages, 
monocytes, etc.). The majority of direct, bacterial-mediated T cell suppression involves the 
induction of lymphocyte apoptosis via bacterial toxins (276, 277). The induction of 
apoptosis by these toxins is often dependent on the T cell's intrinsic apoptotic machinery; 
and is induced due to cellular stress caused by increased cell permeability, inhibition of 
protein production, or direct alteration of signal transduction (276-278). Based on these 
criteria, bacterial toxin induced T cell apoptosis is considered ACAD-like death. 
The indirect lymphosuppression mediated through the activation of innate immune 
cells can occur via lymphocyte apoptosis or suppression without loss of cell viability. The 
induction of apoptosis by indirect means is generally considered a mechanism used by 
intracellular bacteria (276). Bacterial pathogens such as Chlamydia and Mycobacteria spp. 
direct their host cells (usually cells of innate immune system—such as macrophages) to 
induce ACID by orchestrating the delivery of apoptotic signals, such as TNF-a and FasL, to 
T cells (276). It is important to note that other mechanisms of apoptosis have been linked to 
the production of reactive oxygen species, nitric oxide, and TGF-P (235, 239, 249). While 
the majority of studies focused on these effects have been in vitro, resistance of T cells to 
apoptosis during in vitro assays correlates with resistance to chronic infection (279). 
In contrast to the indirect lympho-suppression by apoptosis, multiple species of 
bacteria and/or bacterial products are able to suppress lymphocyte activation through 
induction of innate immune cell products such as TGF-|3, ROS, and NO (254, 255, 280). The 
induction of these products can be mediated by whole bacteria, bacterial cell wall extracts, 
and/or LPS (254, 281-284). Suppression vs. apoptosis may be a question of TGF-|3, ROS, 
and/or NO dose, as these products have also been linked to decrease in lymphocyte viability 
(mentioned above). 
A special case of indirect induction of lymphocyte suppression through activation of 
innate cells, is the production of a cecropin-like peptide (cecropins are anti-microbial 
peptides related to (3-defensins) by H. pylori (285). This 19 amino acid peptide fragment of 
Hsp70 gene product is chemotactic for monocytes and induces the production of ROS able to 
induce apoptosis of naïve lymphocytes and NK cells (280, 286). Interestingly, this peptide 
(known as Hp2-20) is also a bacteriocidin as it displays anti-microbial activity (286). 
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3.8 Mycoplasmas and immunosuppression 
Multiple mycoplasma species have been reported to be immunosuppressive (Table 1). 
To date, the factors involved in mycoplasmal suppression of lymphocyte function have 
largely gone undiscovered. However, some groups have isolated inhibitory or cytotoxic 
mycoplasmal products. The superantigen MAM (M. arthritidis mitogen), produced by M. 
athritidis, is able to suppress lymphocyte proliferation when lymphocytes are isolated from 
MAM immunized mice (287). This phenomenon is not fully understood, but may be due to 
activation induced cell death (AICD) or T cell anergy (288-291). Lipoproteins from M. 
fermentans and M. salivarium have shown cytotoxic effects on transformed lymphocytes and 
monocytes by an unknown mechanism (292, 293). An inflammatory toxin isolated from M. 
bovis was shown to be toxic to cells. The toxin is a 73 kDa polysaccharide containing no 
lipid or protein components (294). Its size and lack of other biomolecules (lipids or proteins) 
suggest that it is an envelope carbohydrate. However, methods used to determine the 
existence of polysaccharide coats produced by mycoplasmas (295) have not detected this 
structure in association with any tested strains of M. bovis (Dr. Ricardo Rosenbusch, Iowa 
State University — personal communication). 
Mycoplasma bovis is included in the group of immunosuppressive mycoplasma by 
modulating both neutrophils and lymphocytes (157, 296). Early research into the study of 
immune responses to M. bovis indicated that peripheral blood mononuclear cells (PBMCs) 
from M. bovis-infected animals have an impaired proliferative response to lectin mitogens in 
vitro, when compared to responses from non-infected animals (297). It was also shown that 
animals infected with M. bovis had a reduction in immune reactivity (298, 299). The effects 
of M. bovis infection on general animal health was subsequently described in a field case 
study conducted in UK. The study reported that calves born to a herd infected with M. bovis 
had a higher rate of mortality due to common pathogens than those born in the herd prior to 
M. bovis introduction (300). While this study could suggest an immunosuppressive ability of 
M. bovis, this hypothesis was never directly tested. 
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Table 2. Examples of immunosuppressive mycoplasma species 
Mycoplasma specie Host Immune Function suppressed Reference 
M. fermentans Human MHC class II expression (301) 
Lymphocyte viability (292) 
Monocyte viability 
M. mycoides spp. Bovine, sheep, goats Lympho-proliferation (302) 
mycoides 
M. meleagridis Turkey Humoral réponses (303) 
M. pneumoniae Human Cellular immunity (304) 
M. athritidis Rat Lympho-proliferation (287) 
M. hyorinis Pig T cell cytotoxicity (305) 
M. ovipneumoniae Sheep Macrophage MHC expression (306) 
M. pulmonis Rats Humoral responses (307) 
Mice Humoral and cellular responses (308) 
M. dispar Bovine Lympho-proliferation (309) 
M. hyopneumoniae Swine Neutrophil Oxidative burst (310) 
Lympho-proliferation (311) 
M. gallisepticum Avian (chicken) Humoral responses (312) 
M. salivarium Human Lymphocyte viability (292) 
Monocyte viability 
M. bovis Bovine Lympho-proliferation, viability (157, 296, 
Neutrophil Oxidative burst 309,313) 
In vitro studies using purified bovine neutrophils indicated that M. bovis is able bind 
to neutrophils and inhibit experimentally induced oxidative burst (157). Additional studies 
were conducted to determine the effects of M. bovis on bovine lymphocytes. C.J. Howard 
and C. Thomas independently showed that M. bovis is able to suppress bovine PBMC 
proliferative responses to lectin mitogens in vitro, and that the mycoplasmal factor(s) is heat 
(30min 56C) but not formalin labile (296, 309). These discoveries coupled with the 
identification of the immune evasion proteins, Vsps, suggest that M. bovis is equipped with 
multiple mechanisms to elude immune clearance subsequently aiding in persistence and 
pathogenicity. 
28 
Since the discovery of mycoplasmal immunosuppression, multiple species have been 
described as modulating immune function. The mechanisms of immune modulation range 
from lymphocyte suppression through induction of apoptosis to down-regulation of immune 
modulatory receptors such as MHC class II (Table 2). Despite years of investigations into 
immunosuppressive phenomena, the molecules responsible for these effects are largely 
unknown. To date no mycoplasmal factor able to inhibit naive lymphocyte function has been 
isolated and/or characterized. 
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CHAPTER 3. MYCOPLASMA BOVIS INDUCES APOPTOSIS OF 
BOVINE LYMPHOCYTES 
A paper published in FEMS Immunology and Medical Microbiology1 
Tony J. Vanden Bush5 and Ricardo F. Rosenbusch* 
Abstract 
We report Mycoplasma bovis induces apoptotic death of bovine lymphocytes. Using 
flow-cytometry analyzed propidium iodide inclusion we observed a loss in viable 
lymphocytes upon incubation of freshly isolated bovine PBMCs with M. bovis. The use of 
Annexin V staining as well as TUNEL assays corroborated these findings. In addition, these 
assays indicated that the M. bovis-induced lymphocyte death is apoptotic in nature. 
Subsequent experiments demonstrated that the prokaryotic protein production inhibitor 
chloramphenicol inhibited lymphocyte death induced by M. bovis, showing that M. bovis 
protein production is necessary for the induction of lymphocyte death, and that the death is 
not dependent upon the addition of apoptotic inducers as shown with other mycoplasma. We 
also show that M. bovis is different from other bovine mycoplasmas (both pathogenic and 
non-pathogenic) with regards to this characteristic. 
1. Introduction 
Mycoplasma bovis is a wall-less prokaryotic (class Mollicutes) pathogen of cattle. 
Recently, M. bovis is gaining attention due to its negative impact on US beef and dairy 
industries, accounting for substantial economic losses annually. While this pathogen is most 
often associated with bovine pneumonia, it has the capability to become systemic causing 
arthritis and mastitis. 
Pathogenic factors have been described for multiple species of mycoplasmas [1], 
Mycoplasma bovis itself has been shown to induce bovine macrophages to produce TNF-
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alpha and nitric oxide, two powerful initiators of immune activity [2], Along with the ability 
to induce immune cells to produce cytokines, previous publications have reported that M. 
bovis can modulate immune cell functions in vitro and in vivo [3-6]. Specifically, M. bovis is 
able to inhibit both mitogen mediated lympho-proliferative responses and neutrophil 
degranulation in vitro [4-6]. Using trypan blue to determine cell viability, it was reported 
that the observed lympho-proliferative suppression of M. bovis was not due to a loss of 
lymphocyte viability [4,5]. Because of the systemic capabilities of Mycoplasma bovis, we 
view its inhibition of lympho-proliferative responses as a potential pathogenic mechanism. 
We therefore studied this suppressive phenomenon in an effort to characterize the interaction 
between bovine lymphocytes and M. bovis. 
2. Materials and Methods 
2.1. Mycoplasma 
Mycoplasma species were obtained either through ATCC (M. bovis Jasper 25025) or 
from Dr. R. Rosenbusch (M. bovis strain M23 [7], M. bovirhinis strain 352i, M. bovocoli 
strain 233, and M. bovocoli strain C52). All Mycoplasma were grown in modified Friis 
broth at 37°C, 2.5% C02 as previously described [8], Mycoplasma were harvested by 
centrifugation (18,000 g for 20 minutes at 4°C), washed 3 times in PBS pH 7.4, and 
suspended at a concentration of 1 mg/ml (BioRad DC protein Assay) in RPMI 1640 complete 
media (RPMI supplemented with 100 units/ml penicillin, 100 jig/ml streptomycin, 2 mM 
Gluta-Max (GibcoBRL), 5 X 10"3 mM (3-mercaptoethanol, 25 mM Hepes, 1 mM sodium 
pyruvate, and 10% fetal bovine serum (FBS)). Washed mycoplasma were stored at -70°C 
until needed. 
2.2. Bovine PBMCs harvest 
Bovine PBMCs were harvested from healthy, Mycoplasma free (by nasal swab), 8 
month old steers (sero-negative for M. bovis) in accordance with animal care regulations. 
Blood drawn from cattle was diluted 1:1 with 37°C PBS and layered on Histopaque 1077 
(Sigma). Upon centrifugation (500 X g for 40 minutes at room temperature), the resulting 
band was collected, washed 2 times in PBS (centrifuged at 250 X g for 10 minutes for each 
wash), and counted. The cells were resuspended in RPMI 1640 complete at the desired 
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concentration depending on the experimental parameters. To ensure that the effect was due 
to M. bovis, cell suspensions were periodically tested for mycoplasmal contamination by 
PGR, and all solutions used were dedicated to individual experiments [9]. Each experiment 
used a single donor calf with each treatment performed in triplicate. Comparing treatment 
samples to an internal control from the same donor generated data for individual 
experiments. Mycoplasmas were added to cell cultures at amounts determined to give 
optimum results. 
2.3. Blastogenesis 
In a 96 well plate format, 4 X 105 PBMCs were incubated with 4 ^ g/ml Con A in the 
presence or absence of various bovine mycoplasmas (200 ng/well). After 44 hours, a trace 
amount of 3H-thymidine was added to each well followed by incubation for an additional 20 
hours. Cells were harvested onto a glass filter and counts per minute (cpm) read by a 
scintillation counter. The proliferative response was measured by stimulation index 
(treatment cpm/media blank cpm). 
2.4. Flow cytometry 
All FACS analyses were performed on a flow cytometer FACScan (Beeton Dickenson), 
acquiring 10,000 events and analyzed using CellQuest FACS software. Percentages are 
based on the population of cells defined as lymphocytes. The population was designated as 
being lymphocytic in nature by previous experiments staining the isolated PBMCs with T 
cell subset markers CD4 and CD8. 
2.4.1. Propidium iodide viability assay 
PBMCs (9 X 105 cells/well) were incubated in a 24 well plate format for 40 hours in the 
presence or absence of M23 or Jasper (200 ng/well) strains of M. bovis. The cells were 
washed 2 times in PBS 1%BSA (FACS buffer) by centrifugation at 200 X g for 7 minutes 
per wash. Cells were then resuspended in 1 ml of FACS buffer containing 1.25 pig/ml 
propidium iodide (PI). PBMCs were subjected to flow analysis and the lymphocyte 
population gated. Chloramphenicol was added to cell cultures (at the same point as the 
mycoplasma, time = 0) to a final concentration of 50 //g/ml. 
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2.4.2. Apoptosis assays 
PBMCs (9 X 105 cells/well) were incubated in a 24 well plate format for 18 hours in the 
presence or absence of M23 (200 ng/well). Cells from each well were then prepared 
according to manufacturers' specifications (Annexin V apoptosis kit, Sigma: TUNEL 
apoptosis kit, R&D systems). In brief, cells were washed 2 times in FACS buffer before 
being subjected to either of the assays. For Annexin binding determination, the cells were 
resuspended in Annexin binding buffer and allowed to incubate at RT with FITC labeled 
Annexin V and PI, all of which were provided with the kit. With regards to the TUNEL 
assay, the washed cells were fixed in 3.7% paraformaldehyde in PBS. Cells were then 
permeablized and incubated with a reaction mixture containing terminal dinucleotide 
transferase enzyme and biotinylated dNTPs. A positive control was generated by adding a 
nuclease (provided) to a control sample of PBMCs (negative for M. bovis) and incubating at 
37°C for 15 minutes prior to incubation with the reaction mixture. The negative control did 
not receive the terminal dinucleotide transferase. The cells were then reacted with FITC 
conjugated streptavidin and washed. After their respective treatments, the cells were 
subjected to flow cytometry and the lymphocyte population gated and analyzed for Annexin 
V and PI staining or an increase in fluorescence intensity (TUNEL). 
To ascertain whether the DNA damage was nuclear or cytoplasmic, cells from the 
TUNEL assay, described above, were placed onto glass slides by centrifugation and analyzed 
by confocal fluorescence microscopy. PBMCs treated with M. bovis, as described, were 
washed, fixed in 3.7% buffered formaldehyde, washed in PBS, and spun onto a glass slide. 
Cell morphology was visualized by creating a digital image through a 100X objective (oil 
immersion) and the digital image increased in size by a zoom factor of 1.25. Images of 
individual cells showing classic apoptotic bodies were cropped and sharpened using 
Photoshop. No images were digitally enhanced. 
DNA laddering was analyzed by the extraction and purification of DNA (Quiagen blood 
kit) from cells incubated with and without M. bovis strain M23 for 24 hours. The DNA was 
then quantified, loaded in a 1.5% agarose gel at equal amounts determined by 260nm 
absorbance, and subjected to electrophoresis. Gels were then stained with ethidium bromide, 
illuminated with UV light, and photographed. 
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2.6. Statistics 
All determinations were done in triplicate wells. Mean values were generated and 
compared by individual t-tests. Values are reported in Table 1 as means ± 2 X standard error 
of the mean (SEM). 
3. Results & Discussion 
3.1. Inhibition of blastogenesis responses is due to Mycoplasma bovis induced 
lymphocyte death. Previous publications have stated that the Jasper strain of Mycoplasma 
bovis, a highly passaged lab strain, is able to inhibit bovine PBMCs lympho-proliferative 
responses to mitogens [4,5]. To determine if the lympho-proliferative inhibitory trait was 
species specific, 2 other bovine mycoplasma species were tested for the inhibitory effect, 
utilizing 3H- thymidine incorporation based blastogenesis. Mycoplasma bovis strains M23 
and Jasper were able to inhibit lympho-proliferative responses to ConA. Neither the non­
pathogenic Mycoplasma bovirhinis nor the ocular pathogen Mycoplasma bovocoli have an 
inhibitory affect on the ConA induced lymphocyte proliferation (Fig. 1). Interestingly, M. 
bovirhinis was able to increase 3H-thymidine uptake by bovine PBMCs in the abscence of 
ConA, indicating that this non-pathogenic mycoplasma has mitogenic capabilites (data not 
shown). Even at a 10 fold increase (protein amounts), M. bovocoli and M. bovirhinis did not 
inhibit ConA stimulated proliferation (data not shown). It was therefore concluded that the 
inhibitory effect of M. bovis is not common to all bovine mycoplasmas, supporting the view 
that the effect may be a specific pathogenic characteristic. 
The blastogenesis results obtained from the M23 strain treated wells were consistent with 
the previously reported results for Jasper strain. Using trypan blue exclusion after 48 hours 
of incubation with Jasper strain, previous publications ruled out that the blastogenesis results 
were due to cell death. This is in contrast to more recent data showing that infection with 
other species of mycoplasma increased death of T cells incubated with ConA [10]. We 
hypothesized that cells susceptible to M. èovw-induced death would be destroyed by 48 hour 
incubation, and not detected by trypan blue exclusion. We therefore used flow analyzed 
propidium iodide (PI) exclusion, a population based technique, to determine cell viability. 
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ConA 233 C52 
M. bovocoli 
352i 
M. bovirhinis 
Fig. 1. Mycoplasma bovis inhibits proliferative responses of PBMC's stimulated with 
ConA. PBMCs were incubated in the presence of ConA, with or without mycoplasmas (1 
jig /ml protein) and subjected to a blastogenesis assay. Columns are average SI ± standard 
deviation. 
Data is represented as stimulation index (SI) and is representative of 3 individual 
experiments. 
SI equals the treatment sample CPM divided by the CPM of the nonstimulated PBMCs 
* Statistical significance (p< 0.05) 
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In propidium iodide viability assays, bovine PBMC preps incubated with either M. 
bovis strain led to a statistically significant increase in PI staining of lymphocytes as 
compared to the negative control (Fig. 2a). Not only was a higher percentage of cells PI 
positive within the lymphocyte population, but the overall percent of cells within the 
lymphocyte gate was decreased (Table 1). Based on the cell scatter information the 
incubation of PBMCs with M. bovis induced a shift in cell size and granularity, creating a 
Table 1. Effects of bovine mycoplasmas on cell numbers within lymphocyte population 
Treatment of PBMCs % total population within 
lymphocyte gate 
Control (RPMI) 82.51% ±2.26 
330 ng/ml Jasper strain M. bovis 65.26% ± 5.60" 
330 ng/ml M23 strain M. bovis 54.85% ± 1.42a 
Control (RPMI)b 60.91% ± 1.96 
330 ng/ml strain C52 M. bovoculib 59.52% ± 1.83 
330 ng/ml strain 352i M. bovirhinisb 71.46% ± 6.93" 
330 ng/ml strain M23 M. bovisb 31.77% ± 4.65" 
a Statistically different from corresponding control value (f-test P < 0.05) 
b PBMCs harvested separately from those in the previous experiment. 
Values are % population ± standard deviation 
new cell population (Fig. 2b, c). These cells were PI positive and correlated well with the 
loss of cells within the lymphocyte gate (Table 1 vs. Fig. 2a and b). Even though there was 
variability in control values between experiments, such as seen in Table 1, the effect on 
lymphocyte viability upon incubation with M. bovis was the same. We note that incubation of 
PBMCs with M. bovirhinis or M. bovoculi did not reduce the number of cells within the 
lymphocyte gate (Table 1) or induce an increase in PI positive cells (data not shown). In 
fact, incubation of PBMCs with M. bovirhinis led to an increase in cells within the 
lymphocyte population as compared to the control. This is consistent with our blastogenesis 
assay observations that M. bovirhinis is mitogenic to bovine PBMCs. 
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Viability assay results with M. bovis are consistent with a decrease in cell viability 
and demonstrate that M. bovis has lymphotoxic capabilities. We therefore consider that the 
previous work proposing M. bovis as an inhibitor of lympho-proliferation should be 
interpreted as an observation consistent with a decline in lymphocyte viability. While the 
inhibition of lymphocyte proliferation is most likely due to a loss in viability and not a 
mechanistic suppression, the phenomenon is still a potential pathogenic mechanism. 
3.2. Lymphocyte death due to Mycoplasma bovis is apoptotic in nature. 
Based on the decrease in lymphocyte size and an increase in granularity, it was 
proposed that the cells were undergoing an apoptotic-like death. To test this hypothesis we 
dual labeled PBMC samples with FITC conjugated Annexin V and PI (Sigma) after 
incubation with or without M. bovis (strain M23). Annexin V binds phosphatidylserine, the 
translocation of which is an early indicator of apoptosis [11]. Since Annexin V enables the 
visualization of early apoptotic events, the incubation time was shortened to 18 hours. 
Incubation with M23 increased the Annexin V positive population as well as the double 
labeled (Annexin V/PI) cell population as compared to the negative control, indicating an 
increase in apoptotic cells (Fig. 3). While the data shows an increase in Annexin+/PI- cells, 
indicative of early apoptosis, the majority of the shift is seen in the double positive (Annexin 
V+/PI+) quadrant. This result could be interpreted as either late apoptosis or necrosis, as 
annexin binding is not limited to apoptotic cells [12]. However, the decrease in cell size and 
increase in granularity shown in Figure 2 combined with the annexin V data from Figure 3 
indicates that the event is apoptosis and not necrosis, as necrotic or oncotic cells increase in 
size and decrease in density [12]. In addition, multiple cells within the M. bovis treated 
group of PBMCs showed the characteristic apoptotic bodies on their surfaces (Fig. 3C). 
These cells were also positive for in situ TUNEL staining (data not shown). 
To ensure that these cells were not activated or mitotic B cells, or necrotic cells 
binding Annexin V, the experiment was repeated using a TUNEL assay (R&D) [12,13]. The 
flow analyzed TUNEL assay showed that incubation with M. bovis induced a PBMC shift in 
fluorescence intensity (Fig. 4). This shift is directly correlated with the amount of DNA 
fragmentation within each cell. DNA fragmentation is a phenomenon closely linked to 
apoptosis. Also, we note that the cell count is lower in the M. bovis treated group. This 
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Fig. 3. M. bovis induces apoptotic death of lymphocytes. PBMCs were stained with Annexin 
V vs. PI after 18 hours incubation with: a) RPMI, or b) M. bovis strain M23. Lymphocyte 
population was gated and analyzed for Annexin (FL1-H) binding and PI incorporation (FL2-
H). Numbers within each quadrant represent the percentage of lymphocytes within that 
quadrant. Each plot is representative of 3 individual experiments. 
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Figure 3C. Apoptotic cells from PBMCs cultured with M. bovis. Confocal bright field image 
of an apoptotic cell (see materials and methods). The arrows indicate apoptotic bodies, 
structures indicative of apoptotsis. These cells represent multiple cells within the field. 
Figure is representative of 3 fields from each of 3 individual experiments 
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Fig. 4. Mycoplasma bovis increases the amount of DNA fragmentation in PBMCs. Bovine 
PMBCs were analyzed using a TUNEL based flow assay for DNA damage after 18 hours of 
incubation with: a) RPMI (solide thin line), or b) M. bovis strain M23 (thick gray line). The 
dashed grey line represents the positive control (see materials and methods). Histogram is 
representative of two individual experiments. M represents cells positive for DNA 
fragmentation. 
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decrease in cell count is the result of cells leaving the lymphocyte gate due to morphological 
changes similar to those seen in figure 2c. These results were also confirmed by observing a 
characteristic DNA ladder, a phenomenon associated with apoptosis, from those PBMCs 
treated with M. bovis (data not shown). 
Based on the translocation of phosphatidylserine, incorporation of PI, morphological 
changes, and an increase in nuclear DNA fragmentation (TUNEL and ladder assays) seen in 
PBMCs infected with M. bovis, we conclude that the incubation of M. bovis with bovine 
PBMCs leads to an induction of lymphocyte apoptosis. 
3.3. Lymphotoxicity is dependent upon M. bovis protein synthesis. 
To determine if the lymphotoxic effect witnessed was dependent upon prokaryotic 
protein production, viability assays, as described previously (PI exclusion), were performed 
on cells incubated in the presence of chloramphenicol (an inhibitor of prokaryotic protein 
production). The addition of this compound at the chosen dose had no effect on lymphocyte 
viability (data not shown). Chloramphenicol was able to inhibit the lymphotoxicity 
otherwise seen in non-chloramphenicol treated wells (Fig. 5). This result shows that the 
lymphotoxic effect is dependent upon mycoplasmal protein production. 
While the addition of M. bovis to PBMCs induces lymphocyte apoptosis, it is not 
clear if this effect is a direct or indirect effect of M. bovis. In response to antigen, cells 
within the culture may have been producing pro-apoptotic peptides or been induced to 
release pre-formed pro-apoptotic peptides [14-16]. We note, however, that if the effect is 
indirect it is still dependent upon mycoplasmal protein production specific to M. bovis, as 
other mycoplasma species did not have the same effect. 
Recent advances in flow cytometry have discredited Annexin V/PI assays as being 
specific for apoptosis [12]. Oncotic cells are also able to bind annexin and are permeable to 
PI, causing difficulty in interpreting results. However, morphological changes can be used to 
distinguish the two types of death. Apoptotic cells are characterized by a decrease in cell 
size and a condensed cytoplasm while oncotic cells are characterized by cellular swelling 
[12]. The cell population resulting from M. bovis infection (Fig 2B and C) is smaller in size 
and shows an increase in granularity, consistent with the morphological changes 
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(filled) Medium blank 
M23 + chloramphenicol 
M23 only 
Propidium iodide 
Fig. 5. Suppression of lymphotoxic effect by chloramphenicol. Propidium iodide exclusion 
in lymphocytes was measured after 40 hours of PBMC incubation with, Medium (filled), 
Medium + chloramphenicol + M. bovis (broken line), or Medium + M. bovis (solid line). 
Histogram is representative of 3 individual experiments. Cells within Ml are PI positive. 
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characterizing apoptosis. In addition, eukaryotic cells undergoing apoptosis exhibit DNA 
fragmentation and laddering due to the cleavage of histone bound DNA, and this effect was 
also observed in M. bovis treated PBMCs. 
Multiple laboratories have described an increase in cell death due to mycoplasmal 
contamination [10,17,18]. However, cell death in these studies was experimentally induced 
by the addition of pro-apoptotic chemicals or peptides. We did not add, nor were any pro-
apoptotic agents present within the cell suspensions as indicated by the low percentage of 
non-viable cells in the control groups from each experiment. 
In conjunction with previous reports of an increase in mycoplasmal-induced cell 
death upon induction of apoptosis by experimental means, endonucleases of mycoplasmal 
origin have been found in association with cultured cells' DNA. However, these nucleases 
were absent from intracellular fractions if the cultured cells were not induced to undergo 
apoptosis [10,17,18]. In short, these researchers failed to see a mycoplasma-based 
exacerbation of cell death in the absence of apoptotic inducers. This observation has been 
used to suggest that mycoplasmal endonucleases are not able to cause apoptosis per se, but 
are simply able to enhance the apoptotic effect once the host cell is permeablized to the 
endonucleases [1]. In our research, M. bovocoli, a bovine pathogen known to produce an 
endonuclease similar in size and activity to that of M. bovis, has no significant effect on the 
viability of lymphocytes (Figure 1 and Table 1)[19]. This, along with the data presented here 
— showing M. bovis as capable of inducing apoptosis without the aid of apoptotic inducers ~ 
indicates that lymphotoxicity is a pathogenic determinant associated with M. bovis. 
The ability of mycoplasmas to induce biologically significant processes in cell culture 
is of great interest as it has been estimated that from 10 to 80% of all tissue cultures are 
contaminated by mycoplasmas [1]. Whereas the importance of these findings is evident to 
researchers working in cell culture, the importance of these activities as mechanisms of 
pathogenesis is still undetermined. This research suggests that lymphocytes may be 
specifically targeted by toxic factor(s), potentially arming Mycoplasma bovis with a unique 
mechanism of pathogenesis. 
The induction of bovine lymphocyte apoptosis by M. bovis, a pathogen causing 
respiratory disease as well as diseases such as arthritis and mastitis, seems counterintuitive; 
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arthritis and other forms of inflammatory diseases are often associated with mass lymphocyte 
infiltration and nonspecific activation, not lymphocyte death [20]. However, M, bovis may 
not be inducing the apoptosis of all lymphocytes in vivo, and the apoptotic effect may not 
inhibit lymphocyte infiltration or the production of pro-inflammatory cytokines by additional 
cell types. Furthermore, the arthritis and mastitis caused by M. bovis are acute and less 
dependent on lymphocyte infiltration and non-specific activation than chronic inflammatory 
disease states. 
We are herein the first to report that: 1) Mycoplasma bovis induces lymphocyte 
death, 2) that M. bovis protein production is necessary for the induction of lymphocyte death, 
3) that the death is apoptotic in nature, and 4) that the death is not dependent upon the 
addition of apoptotic inducers as shown with other mycoplasma. We also show that M. bovis 
is different from other bovine mycoplasmas (both pathogenic and non-pathogenic) with 
regards to this characteristic. 
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Abstract 
Mycoplasma bovis is able to inhibit the mitogen-induced proliferation of bovine 
lymphocytes. Herein is described the isolation of an immuno-inhibitory peptide from M. 
bovis. Using size exclusion chromatography, three lympho-suppressive fractions were 
isolated from M. bovis free supernatant. MALDI-TOF analysis revealed a common peak 
throughout the suppressive fractions. The purest of these fractions was subjected to N-
terminal sequencing, revealing an 84% homologous match with the C-terminus of the M. 
bovis surface protein VspL (variable surface protein - L). A recombinant of the 26 amino 
acid peptide was also able to suppress ConA induced proliferation of bovine lymphocytes. 
This describes a unique immunosuppressive peptide produced by the bovine respiratory 
pathogen, M. bovis. 
Introduction 
Mycoplasmas are wall-less prokaryotes that represent the smallest self-replicating 
organisms known. In comparison to other prokaryotes, mycoplasmas have a relatively small 
genome, limited metabolic activities (may be related to their small genomes), and lack a cell 
wall [1]. Pathogenic species of mycoplasma are of great significance to both human and 
animal health, being linked to diseases such as mastitis, urethritis, arthritis, and pneumonia in 
animals and humans [1-3]. Despite their small genome, these obligatory parasites have 
evolved complex methods of immune evasion including antigenic modulation [4-6], and 
immune cell modification [7-9]. 
Antigenic modulation is accomplished through variations in surface protein 
expression. In the case of M. bovis, a family of highly antigenic proteins known as variable 
surface proteins (Vsps) undergo high rates of recombination [10-12], Through these 
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recombinatory events, individual Vsps can be 'turned off, or their primary structure altered, 
therefore changing the bacteria's antigenic phenotype [5, 13]. In contrast, immune cell 
modulation involves the suppression or alteration of immune cell function. For example, M. 
pulmonis (murine pathogen) is able to suppress DHT responses, M. hyorhinis (porcine 
pathogen) is able to suppress mitogen induced proliferation of PBMCs, and M. pneumoniae 
(human pathogen) is able to suppress cellular immune functions [14-16]. Despite these 
observations, characterization of a mycoplasmal product(s) capable of suppressing naive 
lymphocyte activation has yet to be accomplished. 
Mycoplasma bovis is a pathogen of cattle associated with pneumonia, arthritis, and 
mastitis [17]. This mycoplasma's genome contains multiple vsp genes. In addition to their 
role in immune evasion through antigenic modulation, the Vsps of M bovis have been 
characterized as adhesion factors, orchestrating the attachment of these obligatory parasites 
to host cells [5, 18-20]. Along with the ability to alter its antigenic phenotype, M. bovis is 
presumed to modulate immune function through induction of lymphocyte apoptosis and 
suppression of neutrophil function [7, 8, 21]. To date, no independent function has been 
assigned to an individual vsp gene product. In this study, the isolation of a M. bovis produced 
immunosuppressive peptide homologous to the C-terminus of Vsp-L (Mb-LIP - Mycoplasma 
bovis inhibitory peptide) is described. 
Material and methods 
Bacterial Culture. Mycoplasma bovis strain M23 was grown and maintained in Friis+ 
broth as previously described [22]. 
Peripheral Blood Mononuclear Cell Isolation. Bovine peripheral blood mononuclear 
cells (PBMCs) were isolated as previously described [22]. In brief, blood was collected from 
donor cattle by veinupuncture and mixed 1:10 with 2X ACD (anticoagulant). Whole blood 
was mixed with an equal volume of PBS and layered on lymphocyte separation media 
(CellGrow), and centrifuged at 400 X g for 40 minutes. The resulting band of PBMCs was 
collected. PBMCs were then washed in PBS three times and resuspended in supplemented 
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RPMI 1640 medium (4 X 106 cells/ml). One hundred micro-liters of cell suspension were 
dispensed into the wells of a 96 well, U-bottom culture plate. 
Mb-LIP Isolation. M. bovis from a log phase broth culture were pelleted by 
centrifiigation as previously described. The pellet was resuspended in PBS to wash the 
bacteria, followed by centrifugation. After 3 washes in PBS, the pellet was resuspended at 
35X log phase concentration in PBS:HBSS w/Ca2+ (50/50 v/v) and placed at 37°C for 1.5 
hours. The M. bovis was pelleted by centrifugation, and the supernatant collected. This 
supernatant was subsequently passed through a 50kDa exclusion filter (Millipore). The 
filtrate was lyophilized. The lyophilized sample was resuspended at 5X concentration (3ml) 
and loaded onto a size exclusion column packed with BioGel-4, BioRad (2cm X 70cm). 
Double distilled water was used as the running solution. Five ml fractions were collected and 
lyophilized. Lyophilized samples were resuspended at 10X (0.5ml) in PBS and tested for 
free amine groups (ninhydrin test) and conductivity (to ensure isotonicity for the biological 
assay). Samples displaying both a positive ninhydrin test and conductivity similar to PBS 
control solution were tested for lympho-suppressive capabilities. 
Ninhydrin and conductivity tests. Five pi of test sample was spotted onto a silicon 
coated glass plate (TLC plate). The spots were allowed to dry and then subjected to an 
aerosol of ninhyrdin reagent (0.2% ninhydrin in butanol saturated H%0). The plate was then 
baked at 180°C for 10 minutes. Visible, violet spots were recorded as a positive. 
Conductivity of 10 mis of distilled H2O was calibrated (using a conductivity meter, Fisher 
Scientific Co. serial # 019982) before and after the addition of lOjal of resuspended sample 
(above). Sample conductivity was background corrected and compared to the background 
corrected conductivity of PBS (IOjj.1 into 10ml). 
Lymphocyte Proliferation Assay. Lymphocyte proliferation assays were done as 
previously described [22]. Mitogen stimulation of PBMCs was done by treating plated cells 
(as described above) with ConA (l|j.g/ml final concentration - Sigma). Negative controls 
received equal amounts of PBS instead of ConA. All treatments were performed in triplicate 
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including PBS blanks (negative control). Test samples were 50pl of either chromatographic 
fraction in PBS, recombinant Mb-LIP in PBS (concentrations as designated), or GST-control 
in PBS. Growth media (supplemented RPMI 1640) was then added to individual wells to a 
final volume of 200|il. Treated cells were incubated for 36 hr in a humidified, 37°C 
incubator. At 36 hrs 0.5(j,Ci of 3H-thymidine was added to each well and the samples 
incubated for an additional 12 hrs. Cellular DNA was then harvested onto glass filter paper 
using a cell harvester, and the counts per minute (CPM) determined by a scintilation counter. 
Results are recorded as stimulation indexes (SI). SI is equal to CPM of the treatment divided 
by the CPM of the corresponding negative control (CPM treatment/CPM negative control). 
MALDI-TOF mass spectrometry. Matrix assisted desorption ionization-time of flight 
(MALDI-TOF) mass spectra were recorded using a spectrometer (Thermo BioAnalysis 
DYNAMO). Test sample was diluted 1:5 in distilled H2O. Sample was mixed with matrix 
(ACH - a-cyano-4-hydrocinnamic acid - at 20mg/ml in 50% acetonitrile solution containing 
0.1% TFA) in equal volumes. One jo.1 was then loaded onto the sample spot, dried, and 
loaded into the instrument. 
N-terminal Sequencing. N-terminal sequencing was done by using an automated 
Edman degradation system (Procise Protein Sequencer, Applied Biosystems) according to 
manufacturer's recommended protocols. 
Recombinant Construction. Primers were constructed to amplify the DNA encoding 
the 26 amino acid peptide (NCBI, DNA acquisition # AF162146). Primers were designed 
with BamHl and EcoRl adapters, respectively (capitalized letters are restriction sites) 
GGATCCtctaaaggtgaaaactac and GAATTCtttacttatttgcttttgt. PCR was performed using 
DNA from M. bovis strain M23 (isolated using the Quiagen blood kit) as template DNA. 
Thermocycler program: 90C, 2min, IX: 90C, 1min; 44C, 1.5min; 72C, 2min, 35X; 72C, 
4min. The product was first cloned into the vector pCR®2.1-TOPO® (Invitrogen) and then 
transferred into the pGEX-2T (Amersham Biosciences) vector at the BamHl/EcoRl site. E. 
coli were transformed with the pGEX-2T construct, and the colonies grown on selective 
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media (ampicillin). Colonies were selected, grown in broth culture, and plasmids isolated. 
The inserts were sequenced (Iowa State University - DNA facility) to ensure proper insert 
and frame. Colonies were grown in LB broth (to an OD of 0.600) and expression induced by 
IPTG (adding to a final concentration of 0.5 mM). Induced E. coli were isolated by 
centrifugation and lysed (BugBuster, Novagene) according to manufacturer's instruction. 
Lysed mixture was clarified by centrifugation (13,000 X g for 10 minutes) and the 
supernatant collected. The recombinant GST-fusion protein was isolated using Glutathione 
columns (Amersham Biosciences) by manufacturer's instruction. The recombinant peptide 
was released from bound GST by incubation with 80 Units of thrombin (Amersham 
Biosciences) for 4 hrs at RT. The thrombin and free recombinant peptide were then 
subjected to centrifugation through a lOkDa microcentricon (amincon). This procedure in its 
entirety was also performed on an unrelated GST-construct as a control (denoted GST-con). 
The GST-fusion protein was compared to GST alone and thrombin cleaved GST-fusion by 
SDS-PAGE to ensure production of the recombinant. The filtrate containing the recombinant 
(after thrombin cleavage and lOkDa filtration) was assayed for presence and purity of the 
recombinant Mb-LIP by MALDI (as described previously). 
Western blotting. GST and GST-Mb-LIP fusion proteins were isolated using 
Glutathione columns (Amersham Biosciences) according to manufacturer's instruction and 
run through a 4-15% gradient SDS-PAGE gel (BioRad). Upon separation, proteins were 
blotted to PVDF and the membrane blocked with 5% Nonfat dry milk in PBS containing 
0.1% Tween. Serum was collected from experimentally infected animals as described [23]. 
The serum was diluted in the blocking solution at 1:200 and incubated with the membrane 
for 1 hour at room temperature. The membrane was then washed in PBS-0.1% Tween 3 
times. Peroxidase labeled rabbit anti- bovine was used as the secondary antibody (Jackson 
ImmunoResearch labs) at 1:500 dilution (in PBS-T) and incubated with membrane for 1 hour 
at room temperature. 
An anti-GST antibody (Pierce) was used to verify the presence of both the GST and 
GST-fusion on the PVDF membrane. Using the same blotting and washing procedures as 
above with the following exceptions: primary antibody 1:10,000 and secondary antibody 
80 
(goat anti-mouse) at 1:1000. Visualization of all bands was done by incubating blots in 
substrate mixture (4mg/ml 4-chloro-1 -naphthol in methanol and diluted into PBS at 1:6). 
Results 
Lymphocyte inhibitory factor is secreted from M. bovis 
Live and formalin, but not heat, inactivated M. bovis are able to suppress lectin-
mitogen induced proliferation of bovine lymphocytes, through a mechanism that may be 
associated with loss of lymphocyte viability [8, 21, 23]. To determine if the lympho-
inhibitory factor(s) was easily separated from M. bovis, live M. bovis were incubated in 
PBS/HBSS for 1.5 hours (Materials and Methods). Supernatants were then passed through 
50kDa and lOkDa filters and tested for suppressive function by 3H-thymidine incorporation-
based blastogenesis. Both of the M. bovis free filtrates suppressed the mitogen directed 
proliferation of bovine lymphocytes, indicating that the factor was either secreted or easily 
separated from the bacteria (Fig.l). Retention of biological function (i.e. lympho-
proliferative suppression) after lOkDa filtration suggested that the factor(s) was of a low 
molecular weight. 
Isolation of suppressive fraction 
The suppressive filtrate (50kDa exclusion filter) was subjected to size exclusion 
chromatography in an effort to further isolate the suppressive factor(s). After separation, 
each of the fractions was concentrated and tested for the ability to suppress lymph-
proliferative responses of bovine PBMCs to ConA. To ensure isotonicity within the 
biological assay, only those fractions that maintained a low (equal or below that of PBS) 
conductivity level were tested for suppression of PBMCs (fractions 1-9 - data not shown). 
Fractions 7-9 tested positive for free amine groups by ninhydrin reaction (Table I), and all 
were able to suppress the lympho-proliferation of bovine PBMCs induced by ConA (Fig. 2). 
While all of these fractions were able to significantly decrease the level of lymphocyte 
proliferation, fraction 7 was not as potent an inhibitor as fractions 8 and 9. 
Suppressive fractions were then analyzed by MALDI, to estimate the size and 
concentration of products within the fractions. MALDI analysis of fraction 9 revealed two 
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peaks, one minor and one major (Fig. 3A). The major peak (MW 2891) was believed to be 
the suppressive factor because it was found in all of the suppressive fractions (Table I); while 
the other, minor peak (1606 Da) contained within fraction 9, was not found in all suppressive 
fractions (Table 1). 
Table I. Suppressive fractions contain free amine groups and a common component based on 
molecular mass. 
Fraction Tests 
Fraction Number Ninhydrin 
test 
Conductivity3 Suppression MALDI peakscd 
6 negative isotonic ND ND 
7 positive isotonic slight 
positive^ 
1252, 1616, 1817, 
2505,2525, 2778, 
2891 
8 positive isotonic positive 2503,2525, 2689, 
2777,2890 
9 positive isotonic positive 1616,2891 
10 positive hypertonic ND ND 
a Definition of iso, and hypertonic are based on comparison with PBS. 
b Slightly suppressive fraction decreased the amount of lymphocyte proliferation from control 
wells, but not to the extent of other suppressive fractions (See figure 2). 
0 Bold text signifies the dominant peak by MALDI analysis. 
d Underlined text indicates peaks (MALDI determination) contained in all three suppressive 
fractions. 
ND - Not Determined 
Suppressive peptide is homologous to variable surface protein L (VspL) 
N-terminal sequencing of fraction 9 was used to elucidate the primary amino acid 
sequence of the predominant peptide. N-terminal sequencing of the amino acids 2-20 
revealed a sequence 84% homologous to the C-terminus of a theoretical gene product of M. 
bovis (NCBI protein acquisition # AAD53531) (Fig. 3B). Calculation of the C-terminal 26 
amino acid, theoretical gene product's molecular weight matched the MALDI analysis 
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Figure 1. Mycoplasma bovis free supernatant is able to suppress lympho-proliferation. 
PBMC cultures were incubated with 25% v/v HBSS with or without M. bovis free 
supernatant filtrates passed through either 50 or lOkDa exclusion filters (Material and 
Methods). Cultures were then stimulated with ConA to induce lymphocyte proliferation. 
Filtrates from M. bovis suspension supernatants inhibited ConA lympho-proliferation as 
determined by 3H-thymidine uptake. ^Significantly different than the positive control (HBSS 
+ ConA) P < 0.05, T-test. 
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Figure 2. Chromatography fractions able to suppress lympho-proliferation. Bovine 
PBMC cultures were incubated with 25% v/v PBS with or without fraction components 
(Material and Methods). Cultures were then stimulated with ConA to induce lymphocyte 
proliferation. Fractions 7-9 suppressed lympho-proliferative responses when compared to 
PBS control. Graphed values are average S.I. ± standard deviation. ^Statistically different 
than the positive control (PBS + ConA) P < 0.05, T-test. ^Statistically different from both 
PBS control and fraction #7, P< 0.05, T-test. 
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Figure 3A. MALDI analysis of fraction 9 reveals two components. Suppressive fraction 
#9 (figure 2) was subjected to MALDI to determine the number of components and to 
estimate the molecular weight of components. The analysis revealed 2 peaks (1616 Da, and 
2891 Da). 
3B 
Identities (Query 2-20) = 16/19 (84%), Positives = 17/19 (89%) 
Query: 1 XSKGPNYLPITGFKXGEEAK 20 
SKG NYLPI+GFK GEEAK 
Sbjct: 252 NSKGENYLPISGFKFGEEAK ETKANK 277 
Figure 3B. Fraction 9 dominant peak (2891) is homologous to the C-terminus of VspL 
surface protein of M. bovis. N-terminal sequencing of the suppressive fraction #9 produced 
a 19 amino acid sequence. This sequence was used as a query to search for homologous 
sequences in the NCBI database. The 19 amino acid sequence was 84% homologous to C-
terminus of VspL. 
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(2.87 kDa), confirming its identity as the dominant peak found in the MALDI analysis of 
fraction 9. 
Based on the theoretical sequence information primers were designed that 
encompassed the 26 amino acid peptide. The fragment was amplified (PGR) and used to 
create a GST-fusion recombinant construct. Purification of the peptide was facilitated by 
thrombin cleavage. The recombinant (28 amino acids - GSSN SKGE NYLP ISGF KFGE 
EAKE TKAN K) peptide was able to inhibit bovine PBMC proliferation in response to ConA 
while the GST-Con sample did not (Fig 4). 
Production of Mb-LIP during infection 
Vsp family members have been identified based on their (i) inclusion in a gene loci, 
(ii) open reading frame characteristics, and (iii) lipoprotein targeting sequence and 
containment of repeat regions [24]. Despite years of research, the expression of some Vsps, 
including VspL, is currently undetermined. To ascertain if Mb-LIP is expressed by M bovis 
during a respiratory infection, serum from experimentally infected animals was tested for 
recognition of the GST-Mb-LIP construct. Serum collected post infection reacted with the 
GST-Mb-LIP fusion protein and not with GST alone (Fig. 5). These data indicate that the 
Mb-LIP peptide is produced during an infection. 
Discussion 
A number of short (< 50 amino acids), linear, lympho-suppressive peptides have been 
isolated from the toxins of scorpions and mollusks [25-32], These peptides share a high 
number of cystines (6) within their short (33-37amino acid) sequences. These 6 cystines are 
used to form 3 disulfide bridges within these small peptides, linking these peptides by 
secondary structure [27, 33, 34]. The Mb-LIP peptide however, does not contain cystines, 
therefore excluding it from this group of peptides. One other lympho-suppressive bacterial 
peptide lacking cystines is the cecropin like peptide Hp2-20 produced by Helicobacter pylori 
[35]. 
The immunosuppressive peptide produced by M. bovis described herein marks the 
first mycoplasmal suppressor of naive lymphocytes to be isolated and fully sequenced. The 
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ConA PBS GST-Con 25% Mb-LIP 25% Mb-LIP 6.25% Mb-LIP 3.12% 
Figure 4. Recombinant peptide able to suppress lympho-proliferation. Bovine PBMC 
cultures were incubated in the presence of ConA with or without 50/(l of recombinant 
peptide Mb-LIP in PBS or 50/<l of respective GST-Con thrombin cleavage product. 
^Statistically different from PBS control T-test, p value < 0.05. ^Statistically different from 
both PBS control and other Mb-LIP concentrations, T-test, p value < 0.05. 
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Figure 5. Serum from M. bovis infected calf contains antibodies against Mb-LIP. GST-
Mb-LIP fusion and GST were subjected to SDS-PAGE and transferred to PVDF membranes. 
Monoclonal antibody against GST was used to probe blot A. Serum from M. bovis-infected 
calf was used to probe blot B. Blot C was probed with anti-GST monoclonal antibody. 
Arrow indicates GST-Mb-LIP fusion band. 
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M. arthitidis superantigen MAM {M. arthitidis mitogen) is able to inhibit lymphocyte 
proliferation, but only if the lymphocytes are recovered from a mouse previously immunized 
against MAM, and therefore not naive [36]. This observation is similar to that of an anergic 
response of the cultured lymphocytes, or activation induced cell death [37-39], When 
cultured with naive lymphocytes in the presence of accessory cells, MAM induces lympho-
proliferation [36], Lipoproteins from M. salivarium and M. fermentans are capable of 
inducing the death of transformed monocytes and lymphocytes, but the effect has not been 
documented for naïve lymphocytes [40,41]. The elucidation of Mb-LIP is therefore an 
important step in understanding the interactions between mycoplasmas and their hosts' 
immune systems. 
The inhibition of lymphocyte proliferation may be due to mechanistic suppression or 
the induction of lymphocyte apoptosis by the peptide Mb-LIP. Either of these possibilities 
can be a consequence of direct or indirect mechanisms . Indirect mechanisms would entail 
the employment of eukaryotic devices to suppress or destroy lymphocyte populations, 
through the production of suppressive cytokines (TGF-|3) or pro-apoptotic compounds (ROS, 
FasL, etc.) [42-44], Direct mechanisms would require direct activity of Mb-LIP on 
lymphocytes such as the toxin produced by Staphylococcus aureus, able to directly kill 
lymphocytes [45], 
Due to the increase in transplantation surgery and diagnosis of autoimmune diseases, 
the importance of immunosuppressive molecules in research and modern medicine is evident. 
A recent and attractive application of immunosuppressant peptides is in the treatment of 
multiple sclerosis (MS). Lympho-suppressive peptides isolated from the toxins of 
invertebrates have been successful in treating experimental autoimmune encephalopathy 
(EAE), an experimental mouse model of MS [26, 46]. The potential of Mb-LIP to be used as 
an immunosuppressant is dependent upon multiple factors; even still, the elucidation of Mb-
LIP's activity may open the door to new immunosuppressive drug targets and strategies. 
In addition to the discovery of a novel immunosuppressive peptide, we are herein the 
first to 1) isolate and characterize a mycoplasma product able to inhibit naive lymphocyte 
activation, and 2) define a specific pathogenic function to a Vsp family member. 
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CHAPTER 5. GENERAL CONCLUSIONS 
Summary 
Evasion of host immune clearance is paramount to the survival of any parasitic 
pathogen. The bovine respiratory pathogen Mycoplasma bovis is able to modulate bovine 
lymphocyte function as a possible mechanism of immune evasion. Immune modulation by 
M. bovis through the induction of lymphocyte apoptosis is dependent upon prokaryotic 
protein production, indicating that the mechanism may be related to a M. bovis produced 
lympho-toxin, and not an indirect activation induced cell death (AICD) mechanism. 
Consistent with the hypothesis of a proteinacious product able to directly inhibit 
bovine lymphocyte function, a lympho-suppressive peptide produced by M. bovis was 
identified. This 26 amino acid peptide, referred to as Mb-LIP, is able to inhibit the lympho-
proliferative responses of bovine lymphocytes to the mitogen ConA. This potential lympho-
toxin is easily separated from M. bovis suggesting that it is a secreted product. Owing to its 
homology with the C-terminal end of an externally exposed surface protein (VspL), Mb-LIP 
may be a cleavage product from VspL. Release of such protein fragments by protease 
activity is a recognized mechanism of secretion utilized by several mycoplasma species. 
Recommendations for future research 
The discovery of a novel immunosuppressive peptide can open many areas of 
continuing research. With regards to Mb-LIP, research can be divided into 2 general 
directions based on discipline. The first direction is immunological in nature, and focuses on 
the immunosuppression induced by M. bovis, with particular interests on the mechanism(s) of 
suppression. Introductory studies could determine the effects of Mb-LIP, or M bovis on 
lymphocytes from other species (human or mouse). This would not only compare the species 
specificity of M. bovis effects, but also allow researchers to utilize a larger pool of reagents 
designed for model species. Using purified Mb-LIP, determine the effectiveness of it as an in 
vivo immunosuppressant, and determine if the Mb-LIP mediated lympho-suppression is 
dependent on eukaryotic activation via TGF-|3, FasL, or ROS production. Whether the 
effects of Mb-LIP are direct or indirect, elucidation of its molecular interaction with 
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eukaryotic cells would be of great interest, including determining the receptor for Mb-LIP. 
Elucidating Mb-LIP's mechanisms of lymphocyte inhibition could prove valuable to 
medicine as a prototype for immunosuppressive drugs or the discovery of novel drug targets 
for immunosuppression. 
The second direction is microbiological in nature, and focuses on the regulation of 
Mb-LIP and VspL by M. bovis. It should be determined if Mb-LIP is the only 
immunosuppressive factor produced by M. bovis. The expression of VspL by 
immunosuppressive strains of M. bovis should be tested, i.e. do all M. bovis strains produce 
VspL or Mb-LIP? Are all M. bovis strains immunosuppressive? It should be determined if 
the source of Mb-LIP is the cleavage of surface VspL, cytoplasmic VspL, or if Mb-LIP is not 
a cleavage product of VspL at all. 
Having discovered an immunosuppressive mechanism utilized by M. bovis, defining 
the first mycoplasmal factor able to inhibit naïve lymphocytes, and characterizing a novel 
immunosuppressive peptide, the stage is now set for continued research into the 
immunosuppressive mechanisms used by mycoplasmas as well as other bacterial species. 
Studies into these areas will open new avenues of research culminating in a better 
understanding of mycoplasma/lymphocyte interactions. 
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APPENDIX A: CHARACTERIZATION OF THE IMMUNE RESPONSE 
TO MYCOPLASMA BOVIS LUNG INFECTION 
Article published in the journal, Veterinary Immunology and Immunopathologyf 
Tony J. Vanden Bush§ and Ricardo F. Rosenbusch* 
Abstract 
To better understand the interaction between Mycoplasma bovis and its bovine host, 
we have characterized the immune response generated during an experimental lung infection 
with M. bovis. Proliferation (3H-thymidine blastogenesis) and Thl/Th2 cytokine production 
were used to monitor peripheral cellular immune responses. Flow cytometry analysis was 
used to determine T cell subset activity by CD25 expression. Humoral immune response was 
monitored by the identification of antigen-specific IgGl and IgG2 isotypes over time. Herein 
we show that M. bovis antigen stimulates activation of CD4+ and CD8+ cells in vitro in a 
manner consistent with memory, and that yô-T cells are activated by antigen in a manner 
consistent with innate immunity. In addition, the percent of cells producing IFN-y during 
recall response is equal to that of IL-4 producing cells. Serological analysis shows M. bovis 
stimulates increased production of antigen-specific IgGl while very little IgG2 is produced. 
We therefore submit that experimental lung infection of cattle with M. bovis results in a Th2 
skewed immune response. 
Introduction 
Mycoplasmas are wall-less prokaryotes (class Mollicutes) that encompass a diverse 
group of organisms considered the smallest self-replicating organisms known. While some 
of these (obligatory) parasites are harmless commensals within their hosts, others are capable 
of causing severe disease (Razin, et al., 1998). Mycoplasma bovis is a pathogen of 
considerable importance to beef and dairy industries. While M. bovis is primarily considered 
a respiratory or mammary pathogen (causing pneumonia and/or mastitis), it has the 
f Reprinted with permission of Vet. Immunol. Immunopathol., 2003, (94) pages 23-33 
§ Primary Researcher and Author 
* Corresponding Author. E-mail: rfrosenb@iastate.edu 
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capabilities to become systemic causing several other diseases including arthritis (Pfutzner, et 
al., 1996). 
As with many mycoplasma species, M. bovis has been reported to be both immune 
reactive and immunosuppressive (Razin, et al., 1998). Upon incubation with M. bovis, 
alveolar macrophages are activated and produce TNF-alpha and nitric oxide (Jungi, et al., 
1996). In contrast, M. bovis also displays immunosuppressive characteristics inhibiting 
neutrophil degranulation and oxidative bursts and proliferation of lymphocytes directed by 
mitogens (Finch, 1990; Thomas, et al., 1990; Thomas, et al., 1991). Recently it was 
determined that M. bovis induces bovine lymphocyte apoptosis in vitro (Vanden Bush, et al., 
2002). Despite its deleterious effects on lymphocytes, infected cattle are able to generate 
measurable humoral and cellular immune responses against M. bovis (Howard, et al., 1986). 
The importance of understanding the immune response generated against M. bovis is 
underscored by reports that the immune system is partly responsible for the lung damage in 
mycoplasma-induced pneumonia, as reported in the mouse M. pulmonis infection model 
(Gartner, et al., 1998). Characterization of the immune response to M. bovis is therefore 
critical in understanding the interaction between M. bovis and the bovine immune system, 
and it's potential relation to lung pathology. 
Materials and Methods 
Animals 
Eight 12 week old calves, negative for respiratory mycoplasmas (nasal swab culture) 
and sero-negative for M. bovis (ELISA), were infected by intratracheal inoculation with 25ml 
PBS containing 7 X 109 CFU/ml fresh culture M. bovis strain M23. An additional 10ml of 
inoculum was delivered intranasally (5ml/nostril). Calves were housed at an animal research 
facility located on site. All procedures were done with consent from Iowa State University's 
Animal Use Committee. 
Sample Collection and Preparation 
One day prior to infection, and at indicated times thereafter, PBMCs and/or serum 
was collected from each animal. Blood was collected via venipuncture. Aliquots allowed to 
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clot were then centrifuged and the serum collected and stored at -20°C until use. Other 
aliquots were collected over sodium citrate anticoagulant, and PBMCs isolated (Vanden 
Bush, et al., 2002). In brief, noncoagulated blood sample was diluted 1:2 with 37°C PBS and 
layered on Histopaque 1077 (Sigma). Upon centrifugation (500 X g for 40 minutes at room 
temperature), the resulting band was collected, washed 2 times in PBS (centrifuged at 250 X 
g for 10 minutes for each wash), and cells counted. The cells were resuspended in complete 
media (RPMI 1640 containing 10% FBS - tested BVDV free, 100 units ml"1 penicillin, 100 
pig ml"1 streptomycin, and 2mM Gluta-Max (Gibco BRL, Grand Island, NY)) at the desired 
concentration depending on the experimental parameters. 
Blastogenesis 
In a 96 well plate format, 4 X 105 PBMCs were incubated with either 2/<g/ml ConA, 
1.5^g/ml heat killed M. bovis strain M23 (56°C for 30 min.), or complete media. After 72 
hours, 0.5^Ci of 3H-thymidine was added to each well followed by incubation for an 
additional 20 hours. Cells were harvested onto a glass filter and counts per minute (cpm) 
read by a scintillation counter. The proliferative response was measured by background 
corrected stimulation index (treatment cpm/complete media cpm). 
IFN-y secretion 
In a 96 well plate format, 4 X 105 PBMCs were incubated with either 2/<g/ml ConA, 
l.5^g/ml heat killed M. bovis strain M23, or equal volume PBS (each treatment in triplicate). 
After 72 hours supernatants from individual wells were collected and frozen at -70°C. 
Supematants were tested for IFN-y by Bovi-gam ELIS A (BioCore, Omaha, NE) according to 
manufacturer's instructions. Comparisons were made between the three treatments. Results 
are reprsentative of 2 trials using cells collected from the same group of 4 animals. 
Serum ELISA 
Serum was subjected to antigen-specific, direct or isotype specific ELISA. In brief, 
Tween-20 extracted M. bovis proteins were used to coat an 96 well Immulon I ELISA plate 
at 5/ig protein/well. After antigen attachment, plates were washed 4 times (isotonic saline 
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containing 0.1% Tween, Sal-T), then blocked (1% PCS in Sal-T) for 2 hours at RT. After 
blocking, the plates were washed 3 times with Sal-T and diluted serum samples added to the 
wells in triplicate — serum dilutions for the direct ELISA (using Protein G) were 1:100 
(50mM Tris containing BSA 0.1%, 0.8% saline, and 0.05% Tween 20, TSB-T). The plates 
were then incubated for 30 minutes at 37°C. After incubation, plates were washed 3 times 
with TSB-T, and horse-radish peroxidase conjugated Protein-G (diluted in TSB-T 1:1000 
from lmg/ml stock) added to the wells. The plates were then incubated for an additional 30 
minutes at 37°C, subsequently washed (TSB-T for 3 times), and peroxidase reaction mixture 
(ABTS containing H202 - Kirkegaard and Perry, Gaithersburg, MD) added to each well. 
Isotype-specific ELISAs were performed using serum at 1:20 dilution (in TSB-T). DAS-2 
(mouse anti-bovine IgG2) and DAS-16 (mouse anti-bovine IgGl) monoclonal antibodies 
were gifts from Celia O'Brien (Beltsville, MD) and used as secondary antibodies (1:500 
dilution of ascites fluid) followed by goat anti-mouse HRPO conjugate (Jackson 
Immunologicals, West Grove, PA) at 0.8^g/ml. All incubations were 30 minutes at 37°C 
and were followed by 3 washes with TSB-T (as described above). Peroxidase reaction 
mixture was added to wells and incubated for 10 minutes before reading absorbance at 
405nm. 
To determine comparability between IgGl and IgG2 amounts using DAS-2 and DAS-
16 secondary antibodies, isotype ELISA validations were run and the absorbances compared. 
In brief, one 96 well Immulon I plate was divided in half, and each half coated with serial 
dilutions (in quadruplicate) of either bovine IgGl or IgG2 (Jackson Immunologicals, West 
Grove, PA) normalized to decreasing protein amounts per well. DAS monoclonals and goat 
anti-mouse HRPO conjugated antibody were used in a direct ELISA (as described above). 
Absorbance readings based on IgGl and IgG2 amounts showed no statistical difference 
(P>0.05), thus indicating that relative amounts of serum IgG isotypes could be compared 
using the DAS-2 and DAS-16 monoclonal antibodies. 
Flow Cytometry 
PBMCs were purified and used to seed 96 well plates at 4 X 105 cells per well with or 
without 5//g of heat inactivated M. bovis (Vanden Bush, et al., 2002). After 5 days of 
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incubation the cells were stained with appropriate antibodies, and subjected to flow-
cytometric analysis. For dual labeling of CD25 and T cell subset markers, the PBMCs were 
washed 3 times in PBS containing 0.1% NaN3. The cells were then incubated for 30 minutes 
at 4°C with mouse anti-CD25 and either mouse anti-CD4, mouse anti-CD8, or mouse anti-yô 
TCR (Table 1). Cells were then washed 3 additional times before incubating with 
appropriate fluorochrome-conjugated, isotype-specific secondary antibodies (Table 1). Cells 
were incubated with secondary antibodies for 30 minutes at 4°C according to manufacturer's 
instructions. The cells were then washed 3 times and fixed in PBS 1% formalin, 0.1% NaN3. 
Intracellular cytokine staining was performed in 96 well format. Upon incubation 
with and without M. bovis antigen for 5 days, the culture media was replaced with media 
containing 5/<g/ml Brefeldin A, 25ng/ml PMA, and 1/ig/ml ionomycin and allowed to 
incubate an additional 5 hours. Cells were then washed 2 times in PBS, fixed and 
permeablized using Cytofix/Cytoperm (Becton Dickinson, San Jose, Ca) according to 
manufacturer's instructions. Cells were again washed (using Cytowash - Becton Dickinson) 
and incubated for 30 minutes with mouse anti-bovine IFN-y (biotin-conjugated) or mouse 
anti-bovine IL-4 (Serotech, Raleigh, NC). Cells were again washed and incubated 
respectively with Avidin-PE (Sigma) — according to manufacturer's instructions — or goat 
anti-mouse IgG2b - PE conjugate (Southern Biotechnology Associates, Birmingham, AL) at 
0.5^g/ml. Cells were washed and subjected to flow cytometry analysis. Gates for all flow 
cytometry analysis were determined using appropriate isotype controls (Table 1). 
Statistics 
Flow cytometry analysis was done on a FACScan flow cytometer (Becton 
Dickinson), acquiring 5000 events and data analyzed with CellQuest FACS software. Each 
experiment was repeated 2 times using 2 different groups of four cattle (unless otherwise 
stated). Backgroud corrected percent CD25 positive cells were values from treated cells 
minus values from non-treated cells. In blastogenesis and IFN-y ELISA assays, stimulation 
indexes were calculated as corrected value from treated cells divided by value from non-
treated cells. P-values less than 0.05 were considered statistically significant, analyzed by t-
tests. 
l°Antibody/specificity Isotype Clone/Vendor 2° Antibody/specificity Conjugate 
mouse anti-bo CD25 IgG2a CACTI 08 A / VMRD Pullman, WA goat anti-mouse IgG2a PE 
mouse anti-bo CD4 IgGl CACTI38A / VMRD Pullman, WA goat anti-mouse IgGl FITC 
mouse anti-bo CDS IgGl CACT80C / VMRD Pullman, WA goat anti-mouse IgGl FITC 
mouse anti-bo yô-TCR IgG2b TcRl-N24 / VMRD Pullman, WA goat anti-mouse IgG2b FITC 
mouse anti-bo IFN-y IgGl 7B6 / SeroTec Oxford UK. Avidin PE 
(biotin) 
mouse anti-bo IL-4 IgG2b IOH8 / SeroTec Oxford UK. goat anti-mouse IgG2b PE 
mouse IgG2a isotype CACT108A / VMRD Pullman, WA goat anti-mouse IgG2a PE 
control 
mouse IgGl isotype CACT80C / VMRD Pullman, WA goat anti-mouse IgGl FITC 
control or Avidin PE 
mouse IgG2b isotype TcRl-N24 / VMRD Pullman, WA goat anti-mouse IgG2b FITC 
control 
Table 1. List of the antibodies used for flow cytometric analysis of T cell subset activation and cytokine production. 
All secondary antibodies were purchased from Southern Biotech (Birmingham AL). PE-conjugated avidin was purchased 
from Sigma. 
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Results 
Subset Activation 
The recall responses of peripheral lymphocytes can be used to characterize immune 
cell function to an infection (Rhodes, et al., 2001; Sandbulte, et al., 2002). Lymphocyte 
activation upon incubation with heat inactivated M. bovis was monitored using both 
blastogenesis and fluorescence based detection of CD25 expression. The cells from infected 
animals proliferated in response to antigenic stimulation, and in contrast, those from non-
infected animals did not (FIG. 1). Using dual color analysis of PBMCs from infected 
animals (labeling both the subset marker and CD25), the subset of cells responding to the in 
vitro stimulation was determined. All three T cell subsets CD4, CD8, and yô-T cell groups 
had an increase in the percentage of CD25 positive cells when incubated with heat 
inactivated M. bovis as compared to no antigen addition (FIG. 2). The increase in the 
percentage of CD8/CD25 double positive cells however, was proportionally smaller than 
either the CD4 or yô-T cell subset increases. 
To ensure that the increase in CD25 positive cells was a recall response to antigen 
and not simply an in vitro effect of antigen presentation, PBMCs harvested from infected 
animals were compared to those harvested from non-infected animals (FIG. 2). Expression 
of CD25 on naive animals' CD4 and CD8 groups was statistically lower than those from the 
infected cattle, indicating that the infected animals' cells were responding to M. bovis 
antigen. This confirmed that the CD25 positive PBMCs from infected animals were 
responding to M. bovis antigen in a manner consistent with a memory response. However, 
the yô-T cells of both groups, infected and non-infected, became CD25 positive upon 
stimulation with M. bovis. This is consistent with the view that bovine circulating yô-T cells 
may become activated in an innate immune fashion (Smyth, et al., 2001; Kennedy, et al., 
2002). 
Cytokine production 
To help characterize the type of immune response to M. bovis, IFN-y secretion during 
recall responses was monitored (FIG. 3). PBMCs from infected animals produced IFN-y in 
response to inactivated M. bovis. The IFN-y production was considered to be a result of 
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Figure 1. PBMCs from Mycoplasma bovis infected animals proliferate in response to in vitro 
antigen stimulation. PBMCs from infected (I#l-I#4, 21 dpi) and non-infected (U#l, and 
U#2) animals were purified and incubated with or without heat inactivated M. bovis. 3H-
thymidine uptake was used as an indication of proliferation. Recorded values are averages of 
Stimulation Indexes (SI = CPM treatment/CPM untreated) ± standard deviation. 
^Statistically different from 1 (zero stimulation) P< 0.05. ** Statistically different from 1 
(zero stimulation) P< 0.01 
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Figure 2. All T cell subsets are activated in response to M. bovis antigen. PBMCs were 
harvested from infected (21 dpi, n=4) and non-infected cattle (n=2), incubated with or 
without heat inactivated M. bovis and subsequently labeled for the expression of both 
CD25 and T cell specific subset markers (CD4, CDS and yÔ-TCR). Values are 
background corrected mean percentages of activated T cell subsets ± standard deviation. 
'Statistically different from infected group results (P< 0.05). "Statistically different 
from background (values differ from zero). 
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Figure 3. PBMCs from infected animals secrete IFN-y in response to antigen. Supematants 
from in vitro recall assays (isolated 35 dpi) were subjected to BOVIGAM™ ELISA and the 
relative absorbance (Abs) levels converted to a stimulation index (SI = Abs treated/Abs 
untreated control). * Statistically different from untreated (P< 0.001). "Statistically different 
from untreated (P< 0.05). 
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antigen specific recall response since PBMCs from naive animals did not produce significant 
levels of IFN-y when incubated with M. bovis antigen. 
PBMCs from infected and naive animals were subjected to intracellular cytokine 
staining for IFN-y and IL-4 after incubation with or without M. bovis antigen (FIG. 4A). 
There is a significant difference between infected and non-infected animals in both IFN-y and 
IL-4 production. Percentage (background corrected) of lymphocytes, from infected animals, 
positive for IFN-y production was then compared to the percent of IL-4 producing 
lymphocytes (FIG. 4B). In three of the four infected animals, IL-4 and IFN-y producing cells 
were equal in number i.e. showed no statistical difference. PBMCs from calf I#3 however 
had a statistically greater number of IL-4 than IFN-y producing cells. While the results are 
not conclusive, these data would suggest that the immune response is either mixed, or 
skewed to a Th2 response. To help ascertain if the response is skewed or mixed, antigen-
specific antibody responses were studied. 
Serum Responses 
Sera collected every 7 days over a 63 day period were tested for the presence of 
antigen specific IgG antibodies. All four cattle showed an increase in antigen-specific 
antibody titers over the 63 day period (FIG. 5). These findings are consistent with a 
functional humoral response. 
To better characterize the humoral response, ELISA tests were performed using 
isotype specific (IgGl and IgG2) secondary antibodies to determine if the response had a 
skewed IgG isotype phenotype with regards to IgGl and IgG2. The levels of antigen-
specific IgGl continually increased during the testing period, while IgG2 levels barely rose 
above background levels (FIG. 5B and C). The response was dominated by an IgGl isotype 
production, consistent with a Th2 response corroborating the earlier cytokine data. 
Discussion 
Due to both the immunosuppressive nature of M. bovis and reports that the immune 
response is partly responsible for lung pathology, we have characterized the type of adaptive 
immune response to a M. bovis lung infection. While M. bovis infection does induce a 
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Figure 5A. Mycoplasma bovis infection results in antigen-specific antibody production 
consistent with a Th2 immune response. Serum collected over 9 weeks was subjected to 
antigen-specific ELISA. Total IgG was detected using peroxidase conjugated Protein-G as a 
signaling molecule. Individual points represent the mean of triplicate wells. The graph is 
representative of 4 individual ELISA trials (2 trials for each group of 4 animals). 
I l l  
112 
B 
0.5 -i 
0.45 -
0.4 -
-*-l#l 
— 1 # 2  
0.35 -
1 0.3 -
LO 
$0.25 • 
-*-l#3 
-*-|#4 
1 0-2 ' < 
0.15 • 
0.1 -
0.05 -
14 21 28 ?5 42 
Serum collection dpi 
c 
0.45 -
0.4 -
0.35 • 
l#1 
l#2 
l#3 
l#4 •0.25 -
-9 0.2 -
0.05 -
-1 7 14 21 28 35 42 49 56 63 
Serum collection dpi 
113 
measurable cellular response (Bennett, et al., 1977) (blastogenesis) (Howard, et al., 1986) 
(humoral), neither the subsets of T lymphocytes activated during a recall assay nor the 
phenotype of the response had been identified. CD25 (IL2R-alpha subunit) can be used as an 
indicator of lymphocyte activation as this marker's expression is increased upon activation of 
lymphocytes (Dutton, et al., 1998; Quade, et al., 1999; Endsley, et al., 2002; Sandbulte, et al., 
2002). Using CD25 as an indication of activation we report that the major subsets of T cells 
(CD4, yô-Tcells, and, to a lesser extent, CD8) are all activated during incubation with 
antigen. 
IFN-y production has been used as a measure of cellular immune responsiveness and 
is tightly associated with a Thl immune response. The production of IFN-y was not limited 
to infected animals, as one of the control animal's PBMCs responded to antigen with limited 
production of IFN-y (Fig. 3). The, production of this IFN-y could have come from yô-T cells 
activated in a manner consistent with innate immunity. Previous studies have shown that 
bovine peripheral yô-T cells are able to produce IFN-y (Sopp, et al., 2001). However, the 
level of IFN-y produced by the-PBMCs from the naive animal is significantly lower than that 
of the infected animals. 
As IFN-y production is indicative of a Thl response, IL-4 is an indicator of Th2 
responses. In a murine polarized response (Thl or Th2) there are large increases in 
characteristic cytokines (either IL-4 or IFN-y) and cytokine producing T cells, while the 
opposing cytokine is produced in low amounts by relatively few T cells (Morel, et al., 1998). 
In the bovine, however, clear divisions in cytokine production, i.e. immune response 
phenotype, are not as evident (Brown, et al., 1998). Currently, ratios of IL-4 and IFN-y 
amounts have been used to determine Thl vs. Th2 responsiveness in out-bred animals (Koh, 
et al., 2001). Given that a reliable ELISA for bovine IL-4 has yet to be developed, we 
presented our data as direct comparisons of IFN-y vs. IL-4 producing cells (similar to data 
gathered using an ELISPOT assay). 
Because the driving forces of Thl and Th2 responses include the specific antigen and 
the genetics of the host, a "polarized response" depends on the individual host as well as the 
pathogen. Due to the genetic variables in immune response phenotype, out-bred animals 
often give less polarized responses than in-bred animal models. In the bovine model, high 
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levels of IFN-y, low levels of IL-4 and an increase in IgG2 antigen-specific antibody would 
represent a Thl response (Estes, et al., 1994). A Th2 response would be represented by high 
levels of IL-4, low to moderate levels of IFN-y, and an increase in IgGl antigen-specific 
antibodies (Estes, et al., 1995). Differences in antigen-specific immunoglobulin isotype 
production are largely due to the differing effects of the Thl and Th2 characteristic cytokines 
on B cell function and immunoglobulin gene rearrangement (Estes, et al., 1994; Estes, et al., 
1995). For this reason, ratios of cytokine amounts and antigen-specific, antibody isotype 
determination are used as indicators of response phenotyping. In the case of M. bovis 
experimental infection, the number of PBMCs producing IL-4 was as great or greater than 
the number of PBMCs producing IFN-y. While the number of cells producing IL-4 and IFN-
y are statistically similar, the immunoglobulin phenotype (high levels of Ag-specific IgGl, 
low levels of Ag-specific IgG2) was consistent with a Th2 response. We therefore conclude 
that the immune response mounted against a M. bovis lung infection, while not polarized, is 
skewed toward a Th2 phenotype. This skewed response is consistent with other mycoplasma 
respiratory infections, including Mycoplasma pneumoniae infections of humans and M. 
pulmonis infections of mice (Koh, et al., 2001; Romero-Rojas, et al., 2001). The high level 
of IgGl vs. IgG2 not only aids in our response characterization, but may have serious 
implications with regards to M. bovis caused diseases as it is thought that IgG2 is the superior 
opsonin compared to IgGl. The low IgG2 response may therefore contribute to the 
chronicity of a M. bovis infection [Howard, 1984). 
The activation of CD8 cells by M. bovis was unexpected as M. bovis is an 
extracellular pathogen and CD8 cells are normally activated by intracellular pathogens 
(Harty et. al., 2000). However, antigen presenting cells can "cross-prime" in their antigen 
presenting capabilities, activating CD8 cells with antigen derived from extracellular 
pathogens (Gramme et. al., 2002; Maecker et. al., 2001). Although the upregulation of 
CD25 on the CD8 cells could be attributed to IL-2 production by activated CD4 cells, we 
consider the activation of CD8 cells as antigen driven due to reports of CD8 cells being 
involved in other mycoplasma infections (Gaunson et. al., 2000; Hayakawa et. al., 2002; 
Jones et. al. 2002; Rodriguez et. al., 2000). 
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The impact of cytokines on lung cells during mycoplasmal respiratory disease is not 
currently known. Cytokine production during an immune response to M. bovis may have 
direct effects on lung pathology. The Thl cytokine IFN-y sensitizes human alveolar type II 
cells to FasL mediated apoptosis (Wen, et al., 1997). FasL is expressed on the surface of 
neutrophils and activated lymphocytes (two cell types that migrate to lung during M. bovis 
infection) and has been implicated in the immuno-pathology of mycobacterial and listerial 
infections (Jensen, et al, 1998; Mustafa, et al., 2001). It has been hypothesized that the 
effect of IFN-y on lung cells is a mechanism of natural cell turnover in an organ that is 
continuously exposed to foreign particles (Ahdieh, et al., 2001). The mis-regulation of an 
apoptosis facilitating cytokine, such as IFN-y could potentially have serious consequences. 
In contrast, cytokines of a Th2 response weaken lung cell junctions and slow healing of lung 
tissue (Ahdieh, et al., 2001). Again, the mis-regulation of Th2 cytokines may lead to 
significant lung pathology (Henderson, et al., 2000; Temann, et al., 2002). A mixed or less 
robust immune response to M. bovis may therefore have benefits over a polarized response 
with regards to infection and immune lung damage. 
We here provide the first report that: 1) All lymphocyte subsets are activated in 
response to a Mycoplasma bovis lung infection, 2) Bovine yô-T cells exhibit "innate immune 
reactivity" to Mycoplasma bovis, and 3) The response to M. bovis infection is characterized 
by a Th2-skewed immune response. 
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APPENDIX B: ACTIVATION OF WC1+ yôT CELLS BY 
MYCOPLASMA BOVIS IS CONSISTENT WITH INNATE IMMUNITY 
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Abstract 
While it has been reported that WC1+ yôT cell activation is consistent with an 
adaptive immune response, the role of these cells once activated is still an area of debate. 
Due to the high numbers and unknown importance of yôT cells in the bovine immune 
system, the activation of this and other T cell subsets was monitored for responsiveness to 
Mycoplasma bovis in infected and non-infected cattle. Mycoplasma Zwv/s-driven activation 
of bovine T cell subsets during recall assays was monitored using flow cytometry analysis of 
CD25 expression. Lymphocytes from both infected and non-infected animals were 
monitored over the course of 3 months. During the early stages of the infection (1-49 dpi), 
activation of all T cell subsets was evident. The activity of yôT cells, however, were not 
dependent upon memory, as the activity of cells from non-infected animals was similar to the 
activity from infected animals. Using flow cytometry it was determined that these active yÔT 
cells were WC1+ in phenotype, a distinct subset of yôT cells. We conclude that M. bovis 
activates WC1+/ yôT cells in a manner consistent with innate and not adaptive immunity. 
Introduction 
Innate immune cells are recruited to an area of infection, activated, and phagocytize 
antigen. These cells then activate members of the adaptive arm of the immune system, T 
cells. The primary difference between adaptive and innate immunity is specificity. Innate 
immune cells recognize general bacterial biomolecules, while adaptive immune cells 
recognize specific antigens. 
In mammals, the T cell group consists of three primary subsets, CD4+, CD8+, and the 
yôT cells. The distinction between subsets is based on surface markers and T cell receptor 
phenotype. While the role of CD4+ and CD8+ cells in infection and immunity is well 
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defined, little is known about the roles yôT cells play in immunity. 
Previous studies dealing with the roles of bovine yôT cells indicate that these cells 
may play roles in both innate and adaptive immunity. These cells can act in a memory cell 
capacity, while also able to present antigen to CD4 cells; therefore linking them to innate 
immunity (1,2). Due to their large numbers and prevalence in the lung, we studied yôT cell 
activation with regards to M. bovis infection (3). Our findings indicate that while there may 
be gamma delta cells that act in an adaptive nature, gamma delta cells of the WC1+ 
population are activated during in vitro culture with M. bovis in a manner consistent with 
innate immunity. 
Results and Discussion 
The IL-2 receptor subunit alpha is expressed upon activation of T lymphocytes, and 
can therefore be used as an indication of T lymphocyte activation. Using flow cytometry, it 
was discovered that yôT cells isolated from naïve cattle (non-infected and non-vaccinated) 
were activated in response to M. bovis antigen in vitro. This activation does not appear to be 
driven by CD4 or CDS activation, as these subsets of T cells were not activated within the 
naïve PBMC samples (Fig. 1 & 2). 
Peripheral bovine yôT cells can be divided into 2 subsets based on the expression of 
either CDS or WC1+. Non-CDS yôT cells, or WC1+ cells, constitute from 68 to 90% of the 
peripheral yôT cells in cattle. Using three-color flow cytometry is was determined that the 
yôT cells that were activated expressed WC1 (Fig.3). 
Despite the innate like activation of these T lymphocytes, the cells do not express 
Toll-Like Receptor 4, this however does not rule out the expression of other TLRs (Fig. 4). 
WC1+ cells may play an important role in M bovis immunity as they constitute a large 
percent of the T cells in cattle and respond in an innate immune function. A recent report 
shows that WC1+ cells have little effect on Mycobacterial infections in cattle (4). This may 
or may not reflect the importance of this cell to Mycoplasmal infection, as other infection 
models have shown yôT cells to either be important for survival or not very important to 
immunity (5,6). 
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Figure 1. yô T-cells from naïve cattle become activated upon incubation with M. bovis. 
PBMCs from naïve and infected animals were subjected to an in vitro recall assay using heat 
inactivated M. bovis. A) yô T-cells from naïve animals (n=2) responded to the antigen while 
CD4 and CDS T cells did not (Top). B) All of the T cell subsets from infected animals (n=4) 
became activated upon incubation with M. bovis antigen (Bottom). 
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Figure 3. Activated yô T-cells are WC1+ in phenotype. Tri-color staining of PBMCs from naïve animals incubated with M. 
bovis shows that the CD25+/ yô TCR double positive cells (upper right quadrant) express WC1+. 
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Figure 4. WC1+ / yô T cells does not express Toll-like Receptors 4. RNA was extracted 
from FACs sorted WC1+ T cells and neutrophils. The purified RNA was subjected to RT-
PCR (reverse transcription) using primers specific for TLR-4. L-l, WC1+ RT-PCR w/o 
reverse transcriptase; L-2, WC1+ RNA; L-3, Neutrophil RT-PCR w/o reverse transcriptase; 
L-4, Neutrophil RNA. 
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